BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wee S, Wiederschain D, Maira SM, Loo A, Miller C, deBeaumont R, Stegmeier F, Yao YM, Lengauer C. PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A. 2008;105:13057-13062. [PMID: 18755892 DOI: 10.1073/pnas.0802655105] [Cited by in Crossref: 382] [Cited by in F6Publishing: 345] [Article Influence: 27.3] [Reference Citation Analysis]
Number Citing Articles
1 Yuan Y, Wen W, Yost SE, Xing Q, Yan J, Han ES, Mortimer J, Yim JH. Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer. Sci Rep 2019;9:7509. [PMID: 31101835 DOI: 10.1038/s41598-019-43429-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
2 Gonzalez-Angulo AM, Blumenschein GR Jr. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev 2013;39:313-20. [PMID: 23218708 DOI: 10.1016/j.ctrv.2012.11.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 5.8] [Reference Citation Analysis]
3 Chandrasekhar J, Dick R, Van Veldhuizen J, Koditek D, Lepist EI, McGrath ME, Patel L, Phillips G, Sedillo K, Somoza JR, Therrien J, Till NA, Treiberg J, Villaseñor AG, Zherebina Y, Perreault S. Atropisomerism by Design: Discovery of a Selective and Stable Phosphoinositide 3-Kinase (PI3K) β Inhibitor. J Med Chem 2018;61:6858-68. [PMID: 30015489 DOI: 10.1021/acs.jmedchem.8b00797] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
4 Cui W, Cai Y, Zhou X. Advances in subunits of PI3K class I in cancer. Pathology. 2014;46:169-176. [PMID: 24614719 DOI: 10.1097/pat.0000000000000066] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
5 Barbato S, Solaini G, Fabbri M. MicroRNAs in Oncogenesis and Tumor Suppression. Int Rev Cell Mol Biol 2017;333:229-68. [PMID: 28729026 DOI: 10.1016/bs.ircmb.2017.05.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
6 Pascual J, Turner N. Targeting the PI3-kinase pathway in triple-negative breast cancer. Annals of Oncology 2019;30:1051-60. [DOI: 10.1093/annonc/mdz133] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 17.7] [Reference Citation Analysis]
7 Ortiz-Maldonado V, García-Morillo M, Delgado J. The biology behind PI3K inhibition in chronic lymphocytic leukaemia. Ther Adv Hematol 2015;6:25-36. [PMID: 25642313 DOI: 10.1177/2040620714561581] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
8 Moniz LS, Surinova S, Ghazaly E, Velasco LG, Haider S, Rodríguez-Prados JC, Berenjeno IM, Chelala C, Vanhaesebroeck B. Phosphoproteomic comparison of Pik3ca and Pten signalling identifies the nucleotidase NT5C as a novel AKT substrate. Sci Rep 2017;7:39985. [PMID: 28059163 DOI: 10.1038/srep39985] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
9 van der Mijn JC, Panka DJ, Geissler AK, Verheul HM, Mier JW. Novel drugs that target the metabolic reprogramming in renal cell cancer. Cancer Metab 2016;4:14. [PMID: 27418963 DOI: 10.1186/s40170-016-0154-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 7.2] [Reference Citation Analysis]
10 Schmit F, Utermark T, Zhang S, Wang Q, Von T, Roberts TM, Zhao JJ. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proc Natl Acad Sci U S A 2014;111:6395-400. [PMID: 24737887 DOI: 10.1073/pnas.1323004111] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
11 Erami Z, Khalil BD, Salloum G, Yao Y, LoPiccolo J, Shymanets A, Nürnberg B, Bresnick AR, Backer JM. Rac1-stimulated macropinocytosis enhances Gβγ activation of PI3Kβ. Biochem J 2017;474:3903-14. [PMID: 29046393 DOI: 10.1042/BCJ20170279] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
12 Wu P, Hu Y. Small molecules targeting phosphoinositide 3-kinases. Med Chem Commun 2012;3:1337. [DOI: 10.1039/c2md20044a] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
13 Pinson JA, Zheng Z, Miller MS, Chalmers DK, Jennings IG, Thompson PE. L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target non-conserved Asp862 of PI3Kβ. ACS Med Chem Lett 2013;4:206-10. [PMID: 23795239 DOI: 10.1021/ml300336j] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
14 Wang BD, Yang Q, Ceniccola K, Bianco F, Andrawis R, Jarrett T, Frazier H, Patierno SR, Lee NH. Androgen receptor-target genes in african american prostate cancer disparities. Prostate Cancer 2013;2013:763569. [PMID: 23365759 DOI: 10.1155/2013/763569] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
15 Al-Aidaroos AQ, Yuen HF, Guo K, Zhang SD, Chung TH, Chng WJ, Zeng Q. Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells. J Clin Invest 2013;123:3459-71. [PMID: 23867504 DOI: 10.1172/JCI66824] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
16 López-Knowles E, O'Toole SA, McNeil CM, Millar EK, Qiu MR, Crea P, Daly RJ, Musgrove EA, Sutherland RL. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer. 2010;126:1121-1131. [PMID: 19685490 DOI: 10.1002/ijc.24831] [Cited by in Crossref: 190] [Cited by in F6Publishing: 177] [Article Influence: 15.8] [Reference Citation Analysis]
17 Perreault S, Chandrasekhar J, Cui Z, Evarts J, Hao J, Kaplan JA, Kashishian A, Keegan KS, Kenney T, Koditek D, Lad L, Lepist E, Mcgrath ME, Patel L, Phillips B, Therrien J, Treiberg J, Yahiaoui A, Phillips G. Discovery of a Phosphoinositide 3-Kinase (PI3K) β/δ Inhibitor for the Treatment of Phosphatase and Tensin Homolog (PTEN) Deficient Tumors: Building PI3Kβ Potency in a PI3Kδ-Selective Template by Targeting Nonconserved Asp856. J Med Chem 2017;60:1555-67. [DOI: 10.1021/acs.jmedchem.6b01821] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
18 Jia S, Roberts TM, Zhao JJ. Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol 2009;21:199-208. [PMID: 19200708 DOI: 10.1016/j.ceb.2008.12.007] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 5.9] [Reference Citation Analysis]
19 Dbouk HA. PI3King the right partner: unique interactions and signaling by p110β. Postdoc J 2015;3:71-87. [PMID: 26140278 DOI: 10.14304/surya.jpr.v3n6.8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Gjelaj E, Hamel PA. Distinct epithelial-to-mesenchymal transitions induced by PIK3CA H1047R and PIK3CB. J Cell Sci 2021;134:jcs248294. [PMID: 33526718 DOI: 10.1242/jcs.248294] [Reference Citation Analysis]
21 Ni J, Liu Q, Xie S, Carlson C, Von T, Vogel K, Riddle S, Benes C, Eck M, Roberts T, Gray N, Zhao J. Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent. Cancer Discov 2012;2:425-33. [PMID: 22588880 DOI: 10.1158/2159-8290.CD-12-0003] [Cited by in Crossref: 115] [Cited by in F6Publishing: 76] [Article Influence: 11.5] [Reference Citation Analysis]
22 Jeong JY, Kim KS, Moon JS, Song JA, Choi SH, Kim KI, Kim TH, An HJ. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers. Apoptosis. 2013;18:509-520. [PMID: 23371322 DOI: 10.1007/s10495-013-0807-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
23 Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, Will M, Yellen P, de Stanchina E, Baselga J, Scher HI, Barry ST, Sawyers CL, Chandarlapaty S, Rosen N. Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. Cancer Cell 2015;27:109-22. [PMID: 25544636 DOI: 10.1016/j.ccell.2014.11.008] [Cited by in Crossref: 151] [Cited by in F6Publishing: 134] [Article Influence: 18.9] [Reference Citation Analysis]
24 Zhou J, Chen GB, Tang YC, Sinha RA, Wu Y, Yap CS, Wang G, Hu J, Xia X, Tan P, Goh LK, Yen PM. Genetic and bioinformatic analyses of the expression and function of PI3K regulatory subunit PIK3R3 in an Asian patient gastric cancer library. BMC Med Genomics 2012;5:34. [PMID: 22876838 DOI: 10.1186/1755-8794-5-34] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
25 Singh P, Dar MS, Singh G, Jamwal G, Sharma PR, Ahmad M, Dar MJ. Dynamics of GFP-Fusion p110α and p110β Isoforms of PI3K Signaling Pathway in Normal and Cancer Cells: D ynamicsof GFP-F usion p110α and p110β. J Cell Biochem 2016;117:2864-74. [DOI: 10.1002/jcb.25598] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
26 Ilić N, Roberts TM. Comparing the roles of the p110α and p110β isoforms of PI3K in signaling and cancer. Curr Top Microbiol Immunol 2010;347:55-77. [PMID: 20517719 DOI: 10.1007/82_2010_63] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
27 Venkatakrishnan K, Ecsedy JA. Enhancing value of clinical pharmacodynamics in oncology drug development: An alliance between quantitative pharmacology and translational science. Clin Pharmacol Ther 2017;101:99-113. [PMID: 27804123 DOI: 10.1002/cpt.544] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
28 Mellinghoff IK, Schultz N, Mischel PS, Cloughesy TF. Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol 2012;355:135-69. [PMID: 22015553 DOI: 10.1007/82_2011_178] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
29 Xiong Y, Qu L, Li D, Wang Y, Li T. [Clinical Significance and Mechanism of PI3K p110β Overexpression
 in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2017;20:808-16. [PMID: 29277178 DOI: 10.3779/j.issn.1009-3419.2017.12.03] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Perreault S, Arjmand F, Chandrasekhar J, Hao J, Keegan KS, Koditek D, Lepist EI, Matson CK, McGrath ME, Patel L, Sedillo K, Therrien J, Till NA, Tomkinson A, Treiberg J, Zherebina Y, Phillips G. Discovery of an Atropisomeric PI3Kβ Selective Inhibitor through Optimization of the Hinge Binding Motif. ACS Med Chem Lett 2020;11:1236-43. [PMID: 32551006 DOI: 10.1021/acsmedchemlett.0c00095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Vogt PK, Hart JR, Gymnopoulos M, Jiang H, Kang S, Bader AG, Zhao L, Denley A. Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol 2010;347:79-104. [PMID: 20582532 DOI: 10.1007/82_2010_80] [Cited by in Crossref: 28] [Cited by in F6Publishing: 49] [Article Influence: 2.5] [Reference Citation Analysis]
32 Ma G, Gezer D, Herrmann O, Feldberg K, Schemionek M, Jawhar M, Reiter A, Brümmendorf TH, Koschmieder S, Chatain N. LCP1 triggers mTORC2/AKT activity and is pharmacologically targeted by enzastaurin in hypereosinophilia. Mol Carcinog 2020;59:87-103. [DOI: 10.1002/mc.23131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 Maira SM, Finan P, Garcia-Echeverria C. From the bench to the bed side: PI3K pathway inhibitors in clinical development. Curr Top Microbiol Immunol 2010;347:209-39. [PMID: 20582534 DOI: 10.1007/82_2010_60] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
34 Vadas O, Burke JE, Zhang X, Berndt A, Williams RL. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci Signal. 2011;4:re2. [PMID: 22009150 DOI: 10.1126/scisignal.2002165] [Cited by in Crossref: 193] [Cited by in F6Publishing: 159] [Article Influence: 17.5] [Reference Citation Analysis]
35 Leroy C, Amante RJ, Bentires-Alj M. Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine. Biochem Soc Trans 2014;42:733-41. [PMID: 25109950 DOI: 10.1042/BST20140034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
36 Papa A, Pandolfi PP. The PTEN⁻PI3K Axis in Cancer. Biomolecules 2019;9:E153. [PMID: 30999672 DOI: 10.3390/biom9040153] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 21.3] [Reference Citation Analysis]
37 Grassian AR, Lin F, Barrett R, Liu Y, Jiang W, Korpal M, Astley H, Gitterman D, Henley T, Howes R, Levell J, Korn JM, Pagliarini R. Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT). J Biol Chem 2012;287:42180-94. [PMID: 23038259 DOI: 10.1074/jbc.M112.417832] [Cited by in Crossref: 62] [Cited by in F6Publishing: 45] [Article Influence: 6.2] [Reference Citation Analysis]
38 Maynard J, Emmas SA, Blé FX, Barjat H, Lawrie E, Hancox U, Oakes D, Polanska UM, Barry ST. The use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kβ/δ inhibitor. EJNMMI Res 2016;6:62. [PMID: 27515445 DOI: 10.1186/s13550-016-0220-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
39 Parkman GL, Foth M, Kircher DA, Holmen SL, McMahon M. The role of PI3'-lipid signalling in melanoma initiation, progression and maintenance. Exp Dermatol 2021. [PMID: 34717019 DOI: 10.1111/exd.14489] [Reference Citation Analysis]
40 Pang J, Yang YW, Huang Y, Yang J, Zhang H, Chen R, Dong L, Huang Y, Wang D, Liu J, Li B. P110β Inhibition Reduces Histone H3K4 Di-Methylation in Prostate Cancer. Prostate 2017;77:299-308. [PMID: 27800642 DOI: 10.1002/pros.23271] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
41 Schaaf MB, Jutten B, Keulers TG, Savelkouls KG, Peeters HJ, van den Beucken T, van Schooten F, Godschalk RW, Vooijs M, Rouschop KM. Canonical autophagy does not contribute to cellular radioresistance. Radiotherapy and Oncology 2015;114:406-12. [DOI: 10.1016/j.radonc.2015.02.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
42 Kumar A, Redondo-Muñoz J, Perez-García V, Cortes I, Chagoyen M, Carrera AC. Nuclear but not cytosolic phosphoinositide 3-kinase beta has an essential function in cell survival. Mol Cell Biol 2011;31:2122-33. [PMID: 21383062 DOI: 10.1128/MCB.01313-10] [Cited by in Crossref: 54] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
43 Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L. PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts. J Neurooncol 2011;104:155-67. [PMID: 21188471 DOI: 10.1007/s11060-010-0492-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
44 Ciraolo E, Morello F, Hobbs RM, Wolf F, Marone R, Iezzi M, Lu X, Mengozzi G, Altruda F, Sorba G, Guan K, Pandolfi PP, Wymann MP, Hirsch E. Essential role of the p110beta subunit of phosphoinositide 3-OH kinase in male fertility. Mol Biol Cell 2010;21:704-11. [PMID: 20053680 DOI: 10.1091/mbc.e09-08-0744] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
45 McDonald ER 3rd, de Weck A, Schlabach MR, Billy E, Mavrakis KJ, Hoffman GR, Belur D, Castelletti D, Frias E, Gampa K, Golji J, Kao I, Li L, Megel P, Perkins TA, Ramadan N, Ruddy DA, Silver SJ, Sovath S, Stump M, Weber O, Widmer R, Yu J, Yu K, Yue Y, Abramowski D, Ackley E, Barrett R, Berger J, Bernard JL, Billig R, Brachmann SM, Buxton F, Caothien R, Caushi JX, Chung FS, Cortés-Cros M, deBeaumont RS, Delaunay C, Desplat A, Duong W, Dwoske DA, Eldridge RS, Farsidjani A, Feng F, Feng J, Flemming D, Forrester W, Galli GG, Gao Z, Gauter F, Gibaja V, Haas K, Hattenberger M, Hood T, Hurov KE, Jagani Z, Jenal M, Johnson JA, Jones MD, Kapoor A, Korn J, Liu J, Liu Q, Liu S, Liu Y, Loo AT, Macchi KJ, Martin T, McAllister G, Meyer A, Mollé S, Pagliarini RA, Phadke T, Repko B, Schouwey T, Shanahan F, Shen Q, Stamm C, Stephan C, Stucke VM, Tiedt R, Varadarajan M, Venkatesan K, Vitari AC, Wallroth M, Weiler J, Zhang J, Mickanin C, Myer VE, Porter JA, Lai A, Bitter H, Lees E, Keen N, Kauffmann A, Stegmeier F, Hofmann F, Schmelzle T, Sellers WR. Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. Cell 2017;170:577-592.e10. [PMID: 28753431 DOI: 10.1016/j.cell.2017.07.005] [Cited by in Crossref: 321] [Cited by in F6Publishing: 254] [Article Influence: 64.2] [Reference Citation Analysis]
46 Shuttleworth SJ, Silva FA, Cecil AR, Tomassi CD, Hill TJ, Raynaud FI, Clarke PA, Workman P. Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Curr Med Chem 2011;18:2686-714. [PMID: 21649578 DOI: 10.2174/092986711796011229] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 7.7] [Reference Citation Analysis]
47 Zhang L, Cui J, Leonard M, Nephew K, Li Y, Zhang X. Silencing MED1 sensitizes breast cancer cells to pure anti-estrogen fulvestrant in vitro and in vivo. PLoS One 2013;8:e70641. [PMID: 23936234 DOI: 10.1371/journal.pone.0070641] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
48 Wu S, Wen F, Li Y, Gao X, He S, Liu M, Zhang X, Tian D. PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma. Tumour Biol. 2016;37:8799-8809. [PMID: 26747178 DOI: 10.1007/s13277-015-4691-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
49 Wang Z, Liu Y, Huang S, Fang M. TRAF 6 interacts with and ubiquitinates PIK 3 CA to enhance PI 3K activation. FEBS Lett 2018;592:1882-92. [DOI: 10.1002/1873-3468.13080] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
50 Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014;13:140-156. [PMID: 24481312 DOI: 10.1038/nrd4204] [Cited by in Crossref: 1026] [Cited by in F6Publishing: 954] [Article Influence: 128.3] [Reference Citation Analysis]
51 Niveditha D, Sharma H, Majumder S, Mukherjee S, Chowdhury R, Chowdhury S. Transcriptomic analysis associated with reversal of cisplatin sensitivity in drug resistant osteosarcoma cells after a drug holiday. BMC Cancer 2019;19:1045. [PMID: 31690262 DOI: 10.1186/s12885-019-6300-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
52 Jiang X, Chen S, Asara JM, Balk SP. Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J Biol Chem 2010;285:14980-9. [PMID: 20231295 DOI: 10.1074/jbc.M109.085696] [Cited by in Crossref: 58] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
53 Tiemann U, Marthaler AG, Adachi K, Wu G, Fischedick GU, Araúzo-Bravo MJ, Schöler HR, Tapia N. Counteracting activities of OCT4 and KLF4 during reprogramming to pluripotency. Stem Cell Reports 2014;2:351-65. [PMID: 24672757 DOI: 10.1016/j.stemcr.2014.01.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
54 Cizmecioglu O, Ni J, Xie S, Zhao JJ, Roberts TM. Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN loss. Elife 2016;5:e17635. [PMID: 27700986 DOI: 10.7554/eLife.17635] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
55 Owonikoko TK, Khuri FR. Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation. American Society of Clinical Oncology Educational Book 2013. [DOI: 10.14694/edbook_am.2013.33.e395] [Cited by in Crossref: 10] [Article Influence: 1.1] [Reference Citation Analysis]
56 Deuker MM, McMahon M. Rational targeting of BRAF and PI3-Kinase signaling for melanoma therapy. Mol Cell Oncol 2016;3:e1033095. [PMID: 27314067 DOI: 10.1080/23723556.2015.1033095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
57 Cidado J, Park BH. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia 2012;17:205-16. [PMID: 22865098 DOI: 10.1007/s10911-012-9264-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
58 Saintigny P, Mitani Y, Pytynia KB, Ferrarotto R, Roberts DB, Weber RS, Kies MS, Maity SN, Lin SH, El-Naggar AK. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer 2018;124:3693-705. [PMID: 30289966 DOI: 10.1002/cncr.31600] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
59 Chang H, Cai Z, Roberts TM. The Mechanisms Underlying PTEN Loss in Human Tumors Suggest Potential Therapeutic Opportunities. Biomolecules 2019;9:E713. [PMID: 31703360 DOI: 10.3390/biom9110713] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
60 Halder AK, Cordeiro MNDS. Development of Multi-Target Chemometric Models for the Inhibition of Class I PI3K Enzyme Isoforms: A Case Study Using QSAR-Co Tool. Int J Mol Sci 2019;20:E4191. [PMID: 31461863 DOI: 10.3390/ijms20174191] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
61 Giordanetto F, Barlaam B, Berglund S, Edman K, Karlsson O, Lindberg J, Nylander S, Inghardt T. Discovery of 9-(1-phenoxyethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as oral PI3Kβ inhibitors, useful as antiplatelet agents. Bioorganic & Medicinal Chemistry Letters 2014;24:3936-43. [DOI: 10.1016/j.bmcl.2014.07.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
62 De Santis MC, Gulluni F, Campa CC, Martini M, Hirsch E. Targeting PI3K signaling in cancer: Challenges and advances. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2019;1871:361-6. [DOI: 10.1016/j.bbcan.2019.03.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
63 Barlaam B, Cosulich S, Degorce S, Fitzek M, Giordanetto F, Green S, Inghardt T, Hennequin L, Hancox U, Lambert-van der Brempt C, Morgentin R, Pass S, Plé P, Saleh T, Ward L. Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours. Bioorganic & Medicinal Chemistry Letters 2014;24:3928-35. [DOI: 10.1016/j.bmcl.2014.06.040] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
64 Ye Y, Tang X, Sun Z, Chen S. Upregulated WDR26 serves as a scaffold to coordinate PI3K/ AKT pathway-driven breast cancer cell growth, migration, and invasion. Oncotarget 2016;7:17854-69. [PMID: 26895380 DOI: 10.18632/oncotarget.7439] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
65 Wu P, Su Y, Guan X, Liu X, Zhang J, Dong X, Huang W, Hu Y. Identification of novel piperazinylquinoxaline derivatives as potent phosphoinositide 3-kinase (PI3K) inhibitors. PLoS One 2012;7:e43171. [PMID: 22905224 DOI: 10.1371/journal.pone.0043171] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
66 Vogt PK, Gymnopoulos M, Hart JR. PI 3-kinase and cancer: changing accents. Curr Opin Genet Dev 2009;19:12-7. [PMID: 19185485 DOI: 10.1016/j.gde.2008.11.011] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 4.3] [Reference Citation Analysis]
67 He C, Duan S, Dong L, Wang Y, Hu Q, Liu C, Forrest ML, Holzbeierlein JM, Han S, Li B. Characterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells. Prostate 2017;77:1187-98. [PMID: 28631436 DOI: 10.1002/pros.23377] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
68 Weng W, Feng J, Qin H, Ma Y. Molecular therapy of colorectal cancer: progress and future directions. Int J Cancer 2015;136:493-502. [PMID: 24420815 DOI: 10.1002/ijc.28722] [Cited by in Crossref: 13] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
69 Nylander S, Kull B, Björkman JA, Ulvinge JC, Oakes N, Emanuelsson BM, Andersson M, Skärby T, Inghardt T, Fjellström O, Gustafsson D. Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor: Human target validation of PI3Kβ inhibition. Journal of Thrombosis and Haemostasis 2012;10:2127-36. [DOI: 10.1111/j.1538-7836.2012.04898.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 77] [Article Influence: 8.3] [Reference Citation Analysis]
70 Wang Q, Liu P, Spangle JM, Von T, Roberts TM, Lin NU, Krop IE, Winer EP, Zhao JJ. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Oncogene 2016;35:3607-12. [PMID: 26500061 DOI: 10.1038/onc.2015.406] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
71 Schmitt-Hoffner F, van Rijn S, Toprak UH, Mauermann M, Rosemann F, Heit-Mondrzyk A, Hübner JM, Camgöz A, Hartlieb S, Pfister SM, Henrich KO, Westermann F, Kool M. FOXR2 Stabilizes MYCN Protein and Identifies Non-MYCN-Amplified Neuroblastoma Patients With Unfavorable Outcome. J Clin Oncol 2021;:JCO2002540. [PMID: 34110923 DOI: 10.1200/JCO.20.02540] [Reference Citation Analysis]
72 Sharma NS, Gupta VK, Garrido VT, Hadad R, Durden BC, Kesh K, Giri B, Ferrantella A, Dudeja V, Saluja A, Banerjee S. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J Clin Invest 2020;130:451-65. [PMID: 31613799 DOI: 10.1172/JCI127515] [Cited by in Crossref: 39] [Cited by in F6Publishing: 22] [Article Influence: 19.5] [Reference Citation Analysis]
73 Wang X, Xu X, Jiang G, Zhang C, Liu L, Kang J, Wang J, Owusu L, Zhou L, Zhang L, Li W. Dihydrotanshinone I inhibits ovarian cancer cell proliferation and migration by transcriptional repression of PIK3CA gene. J Cell Mol Med 2020;24:11177-87. [PMID: 32860347 DOI: 10.1111/jcmm.15660] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
74 Meng X, Wu SH, Li YY, Tian D. Expression of PI3Kp110α and PI3Kp110β in colorectal canceration. Shijie Huaren Xiaohua Zazhi 2013; 21(8): 661-666 [DOI: 10.11569/wcjd.v21.i8.661] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
75 Zhao JJ, Silver DP. Estrogen receptor-negative breast cancer: new insights into subclassification and targeting. Clin Cancer Res. 2009;15:6309-6310. [PMID: 19825953 DOI: 10.1158/1078-0432.ccr-09-2010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
76 Sanchez RM, Erhard K, Hardwicke MA, Lin H, McSurdy-Freed J, Plant R, Raha K, Rominger CM, Schaber MD, Spengler MD. Synthesis and structure-activity relationships of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones as novel series of potent β isoform selective phosphatidylinositol 3-kinase inhibitors. Bioorg Med Chem Lett. 2012;22:3198-3202. [PMID: 22475557 DOI: 10.1016/j.bmcl.2012.03.039] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
77 Taylor C, Mannion D, Miranda F, Karaminejadranjbar M, Herrero-Gonzalez S, Hellner K, Zheng Y, Bartholomeusz G, Bast RC Jr, Ahmed AA. Loss of PFKFB4 induces cell death in mitotically arrested ovarian cancer cells. Oncotarget 2017;8:17960-80. [PMID: 28152500 DOI: 10.18632/oncotarget.14910] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
78 Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215-1228. [PMID: 26000489 DOI: 10.1016/j.cell.2015.05.001] [Cited by in Crossref: 1591] [Cited by in F6Publishing: 1194] [Article Influence: 227.3] [Reference Citation Analysis]
79 Tan DSW, Adjei AA. Toward High-Precision Genomic Biomarkers: The Importance of Context. J Thorac Oncol 2015;10:1237-9. [PMID: 26291006 DOI: 10.1097/JTO.0000000000000633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
80 Kim K, Lee HW. Expression of Phosphoinositide 3-Kinase p110α and p110β Subunits and PIK3CA Mutation in Patients With Advanced Gastric Carcinoma. Appl Immunohistochem Mol Morphol 2018;26:740-8. [PMID: 28549032 DOI: 10.1097/PAI.0000000000000524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
81 Weigelt B, Downward J. Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer. Front Oncol 2012;2:109. [PMID: 22970424 DOI: 10.3389/fonc.2012.00109] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 5.4] [Reference Citation Analysis]
82 Brana I, Siu LL. Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med 2012;10:161. [PMID: 23232172 DOI: 10.1186/1741-7015-10-161] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 6.5] [Reference Citation Analysis]
83 Hirsch E, Braccini L, Ciraolo E, Morello F, Perino A. Twice upon a time: PI3K's secret double life exposed. Trends in Biochemical Sciences 2009;34:244-8. [DOI: 10.1016/j.tibs.2009.02.003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 3.7] [Reference Citation Analysis]
84 Gris-Oliver A, Ibrahim YH, Rivas MA, García-García C, Sánchez-Guixé M, Ruiz-Pace F, Viaplana C, Pérez-García JM, Llombart-Cussac A, Grueso J, Parés M, Guzmán M, Rodríguez O, Anton P, Cozar P, Calvo MT, Bruna A, Arribas J, Caldas C, Dienstmann R, Nuciforo P, Oliveira M, Cortés J, Serra V. PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. Br J Cancer 2021;124:1581-91. [PMID: 33723394 DOI: 10.1038/s41416-021-01293-1] [Reference Citation Analysis]
85 Bowles DW, Jimeno A. New phosphatidylinositol 3-kinase inhibitors for cancer. Expert Opin Investig Drugs 2011;20:507-18. [PMID: 21395485 DOI: 10.1517/13543784.2011.562192] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
86 Kobylarz MJ, Goodwin JM, Kang ZB, Annand JW, Hevi S, O'Mahony E, McAllister G, Reece-Hoyes J, Wang Q, Alford J, Russ C, Lindeman A, Beibel M, Roma G, Carbone W, Knehr J, Loureiro J, Antczak C, Wiederschain D, Murphy LO, Menon S, Nyfeler B. An iron-dependent metabolic vulnerability underlies VPS34-dependence in RKO cancer cells. PLoS One 2020;15:e0235551. [PMID: 32833964 DOI: 10.1371/journal.pone.0235551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
87 Carvalho S, Milanezi F, Costa JL, Amendoeira I, Schmitt F. PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer. Virchows Arch 2010;456:235-43. [PMID: 20130907 DOI: 10.1007/s00428-010-0881-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
88 Iyengar S, Clear A, Bödör C, Maharaj L, Lee A, Calaminici M, Matthews J, Iqbal S, Auer R, Gribben J, Joel S. P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood 2013;121:2274-84. [PMID: 23341541 DOI: 10.1182/blood-2012-10-460832] [Cited by in Crossref: 79] [Cited by in F6Publishing: 77] [Article Influence: 8.8] [Reference Citation Analysis]
89 Zhang Z, Liu J, Wang Y, Tan X, Zhao W, Xing X, Qiu Y, Wang R, Jin M, Fan G, Zhang P, Zhong Y, Kong D. Phosphatidylinositol 3-kinase β and δ isoforms play key roles in metastasis of prostate cancer DU145 cells. FASEB J 2018;32:5967-75. [PMID: 29792732 DOI: 10.1096/fj.201800183R] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
90 Smyth LM, Monson KR, Jhaveri K, Drilon A, Li BT, Abida W, Iyer G, Gerecitano JF, Gounder M, Harding JJ, Voss MH, Makker V, Ho AL, Razavi P, Iasonos A, Bialer P, Lacouture ME, Teitcher JB, Erinjeri JP, Katabi N, Fury MG, Hyman DM. A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Invest New Drugs 2017;35:742-50. [PMID: 28281183 DOI: 10.1007/s10637-017-0445-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
91 Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, Li BT, Shen R, Vasan N, Modi S, Jhaveri K, Caravella BA, Patil S, Selenica P, Zamora S, Cowan AM, Comen E, Singh A, Covey A, Berger MF, Hudis CA, Norton L, Nagy RJ, Odegaard JI, Lanman RB, Solit DB, Robson ME, Lacouture ME, Brogi E, Reis-Filho JS, Moynahan ME, Scaltriti M, Chandarlapaty S. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nat Cancer 2020;1:382-93. [PMID: 32864625 DOI: 10.1038/s43018-020-0047-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 15.5] [Reference Citation Analysis]
92 Sullivan RJ, Fisher DE. Understanding the biology of melanoma and therapeutic implications. Hematol Oncol Clin North Am 2014;28:437-53. [PMID: 24880940 DOI: 10.1016/j.hoc.2014.02.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
93 Shin N, Stubbs M, Koblish H, Yue EW, Soloviev M, Douty B, Wang KH, Wang Q, Gao M, Feldman P, Yang G, Hall L, Hansbury M, O'Connor S, Leffet L, Collins R, Katiyar K, He X, Waeltz P, Collier P, Lu J, Li YL, Li Y, Liu PCC, Burn T, Covington M, Diamond S, Shuey D, Roberts A, Yeleswaram S, Hollis G, Metcalf B, Yao W, Huber R, Combs A, Newton R, Scherle P. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy. J Pharmacol Exp Ther 2020;374:211-22. [PMID: 32345620 DOI: 10.1124/jpet.120.265538] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
94 Blay J. Updating progress in sarcoma therapy with mTOR inhibitors. Annals of Oncology 2011;22:280-7. [DOI: 10.1093/annonc/mdq307] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
95 Paplomata E, O'Regan R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol. 2014;6:154-166. [PMID: 25057302 DOI: 10.1177/1758834014530023] [Cited by in Crossref: 197] [Cited by in F6Publishing: 191] [Article Influence: 24.6] [Reference Citation Analysis]
96 Beaver JA, Gustin JP, Yi KH, Rajpurohit A, Thomas M, Gilbert SF, Rosen DM, Ho Park B, Lauring J. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. Clin Cancer Res 2013;19:5413-22. [PMID: 23888070 DOI: 10.1158/1078-0432.CCR-13-0884] [Cited by in Crossref: 61] [Cited by in F6Publishing: 46] [Article Influence: 6.8] [Reference Citation Analysis]
97 Csolle MP, Ooms LM, Papa A, Mitchell CA. PTEN and Other PtdIns(3,4,5)P3 Lipid Phosphatases in Breast Cancer. Int J Mol Sci 2020;21:E9189. [PMID: 33276499 DOI: 10.3390/ijms21239189] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
98 Baîram D, Aissa I, Louati H, Othman H, Abdelkafi-Koubaa Z, Krayem N, El Ayeb M, Srairi-Abid N, Marrakchi N, Gargouri Y. Biochemical and monolayer characterization of Tunisian snake venom phospholipases. Int J Biol Macromol 2016;89:640-6. [PMID: 27164498 DOI: 10.1016/j.ijbiomac.2016.05.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
99 Zhang C, Zhang X, Gong Y, Li T, Yang L, Xu W, Dong L. Role of the lncRNA-mRNA network in atherosclerosis using ox-low-density lipoprotein-induced macrophage-derived foam cells. Mol Omics 2020;16:543-53. [PMID: 32915179 DOI: 10.1039/d0mo00077a] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
100 Utermark T, Schmit F, Lee SH, Gao X, Schaffhausen BS, Roberts TM. The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type. J Virol 2014;88:10673-9. [PMID: 24991009 DOI: 10.1128/JVI.01409-14] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
101 Zaballos MA, Santisteban P. Key signaling pathways in thyroid cancer. J Endocrinol 2017;235:R43-61. [PMID: 28838947 DOI: 10.1530/JOE-17-0266] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 8.4] [Reference Citation Analysis]
102 Chopra SS, Jenney A, Palmer A, Niepel M, Chung M, Mills C, Sivakumaren SC, Liu Q, Chen JY, Yapp C, Asara JM, Gray NS, Sorger PK. Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. Cell Syst 2020;10:66-81.e11. [PMID: 31812693 DOI: 10.1016/j.cels.2019.11.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
103 Chin YR, Yuan X, Balk SP, Toker A. PTEN-deficient tumors depend on AKT2 for maintenance and survival. Cancer Discov. 2014;4:942-955. [PMID: 24838891 DOI: 10.1158/2159-8290.cd-13-0873] [Cited by in Crossref: 54] [Cited by in F6Publishing: 42] [Article Influence: 6.8] [Reference Citation Analysis]
104 Dowdle WE, Nyfeler B, Nagel J, Elling RA, Liu S, Triantafellow E, Menon S, Wang Z, Honda A, Pardee G, Cantwell J, Luu C, Cornella-Taracido I, Harrington E, Fekkes P, Lei H, Fang Q, Digan ME, Burdick D, Powers AF, Helliwell SB, D'Aquin S, Bastien J, Wang H, Wiederschain D, Kuerth J, Bergman P, Schwalb D, Thomas J, Ugwonali S, Harbinski F, Tallarico J, Wilson CJ, Myer VE, Porter JA, Bussiere DE, Finan PM, Labow MA, Mao X, Hamann LG, Manning BD, Valdez RA, Nicholson T, Schirle M, Knapp MS, Keaney EP, Murphy LO. Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo. Nat Cell Biol. 2014;16:1069-1079. [PMID: 25327288 DOI: 10.1038/ncb3053] [Cited by in Crossref: 307] [Cited by in F6Publishing: 302] [Article Influence: 38.4] [Reference Citation Analysis]
105 Jiang J, Sun X, Zhu J, Ma J, Luan J, Liu S. [Genetic characteristics and research progress of targeted therapy in squamous cell carcinoma]. Zhongguo Fei Ai Za Zhi 2015;18:172-8. [PMID: 25800575 DOI: 10.3779/j.issn.1009-3419.2015.03.08] [Reference Citation Analysis]
106 Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014;6:377-387. [PMID: 24440717 DOI: 10.1016/j.celrep.2013.12.035] [Cited by in Crossref: 170] [Cited by in F6Publishing: 163] [Article Influence: 21.3] [Reference Citation Analysis]
107 Owonikoko TK, Khuri FR. Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation. Am Soc Clin Oncol Educ Book. 2013;. [PMID: 23714559 DOI: 10.1200/EdBook_AM.2013.33.e395] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
108 Cocco S, Piezzo M, Calabrese A, Cianniello D, Caputo R, Lauro VD, Fusco G, Gioia GD, Licenziato M, De Laurentiis M. Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. Int J Mol Sci 2020;21:E4579. [PMID: 32605126 DOI: 10.3390/ijms21134579] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
109 Leslie NR, Longy M. Inherited PTEN mutations and the prediction of phenotype. Seminars in Cell & Developmental Biology 2016;52:30-8. [DOI: 10.1016/j.semcdb.2016.01.030] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 9.0] [Reference Citation Analysis]
110 Bernatchez C, Cooper ZA, Wargo JA, Hwu P, Lizée G. Novel Treatments in Development for Melanoma. In: Kaufman HL, Mehnert JM, editors. Melanoma. Cham: Springer International Publishing; 2016. pp. 371-416. [DOI: 10.1007/978-3-319-22539-5_16] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
111 Barve A, Jain A, Liu H, Jin W, Cheng K. An enzyme-responsive conjugate improves the delivery of a PI3K inhibitor to prostate cancer. Nanomedicine: Nanotechnology, Biology and Medicine 2016;12:2373-81. [DOI: 10.1016/j.nano.2016.07.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
112 Kashiyama T, Oda K, Ikeda Y, Shiose Y, Hirota Y, Inaba K, Makii C, Kurikawa R, Miyasaka A, Koso T, Fukuda T, Tanikawa M, Shoji K, Sone K, Arimoto T, Wada-Hiraike O, Kawana K, Nakagawa S, Matsuda K, McCormick F, Aburatani H, Yano T, Osuga Y, Fujii T. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. PLoS One 2014;9:e87220. [PMID: 24504419 DOI: 10.1371/journal.pone.0087220] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
113 Dbouk HA, Pang H, Fiser A, Backer JM. A biochemical mechanism for the oncogenic potential of the p110beta catalytic subunit of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A 2010;107:19897-902. [PMID: 21030680 DOI: 10.1073/pnas.1008739107] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
114 Kubala MH, Punj V, Placencio-Hickok VR, Fang H, Fernandez GE, Sposto R, DeClerck YA. Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer. Cell Rep 2018;25:2177-2191.e7. [PMID: 30463014 DOI: 10.1016/j.celrep.2018.10.082] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 13.3] [Reference Citation Analysis]
115 Owusu-Brackett N, Zhao M, Akcakanat A, Evans KW, Yuca E, Dumbrava EI, Janku F, Meric-Bernstam F. Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss. Oncotarget 2020;11:969-81. [PMID: 32215185 DOI: 10.18632/oncotarget.27503] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
116 Majewski T, Yao H, Bondaruk J, Chung W, Lee S, Lee JG, Zhang S, Cogdell D, Yang G, Choi W, Dinney C, Grossman HB, Logothetis C, Scherer SE, Guo CC, Zhang L, Wei P, Weinstein JN, Issa JP, Baggerly K, McConkey DJ, Czerniak B. Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Rep 2019;26:2241-2256.e4. [PMID: 30784602 DOI: 10.1016/j.celrep.2019.01.095] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
117 Certal V, Halley F, Virone-oddos A, Thompson F, Filoche-rommé B, El-ahmad Y, Carry J, Delorme C, Karlsson A, Abecassis P, Vincent L, Bonnevaux H, Nicolas J, Morales R, Michot N, Vade I, Louboutin A, Perron S, Doerflinger G, Tric B, Monget S, Lengauer C, Schio L. Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kβ inhibitors. Bioorganic & Medicinal Chemistry Letters 2012;22:6381-4. [DOI: 10.1016/j.bmcl.2012.08.072] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
118 Houslay DM, Anderson KE, Chessa T, Kulkarni S, Fritsch R, Downward J, Backer JM, Stephens LR, Hawkins PT. Coincident signals from GPCRs and receptor tyrosine kinases are uniquely transduced by PI3Kβ in myeloid cells. Sci Signal 2016;9:ra82. [PMID: 27531651 DOI: 10.1126/scisignal.aae0453] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
119 Nastoupil LJ, Neelapu SS, Davis RE, Samaniego F, Fowler NH, Westin J, Lee HJ, Wang M, Hagemeister F, Cecil ARL, Dow J, Haque K, Silva FA, Whale A, Lensun L, Bone EA, McElwaine-Johnn H, Beer PA. Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma. Leuk Lymphoma 2021;:1-11. [PMID: 34365878 DOI: 10.1080/10428194.2021.1957874] [Reference Citation Analysis]
120 Raimbault A, Itzykson R, Willems L, Rousseau A, Chapuis N, Mathis S, Clauser S, Radford‐weiss I, Bouscary D, Fontenay M, Kosmider O, Bardet V. The fraction of CD117/c‐KIT‐expressing erythroid precursors predicts ESA response in low‐risk myelodysplastic syndromes. Cytometry 2018;96:215-22. [DOI: 10.1002/cyto.b.21781] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
121 Wise HM, Hermida MA, Leslie NR. Prostate cancer, PI3K, PTEN and prognosis. Clin Sci (Lond) 2017;131:197-210. [PMID: 28057891 DOI: 10.1042/CS20160026] [Cited by in Crossref: 77] [Cited by in F6Publishing: 60] [Article Influence: 15.4] [Reference Citation Analysis]
122 Costa C, Ebi H, Martini M, Beausoleil SA, Faber AC, Jakubik CT, Huang A, Wang Y, Nishtala M, Hall B, Rikova K, Zhao J, Hirsch E, Benes CH, Engelman JA. Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. Cancer Cell 2015;27:97-108. [PMID: 25544637 DOI: 10.1016/j.ccell.2014.11.007] [Cited by in Crossref: 132] [Cited by in F6Publishing: 111] [Article Influence: 16.5] [Reference Citation Analysis]
123 Rodon J, Braña I, Siu LL, De Jonge MJ, Homji N, Mills D, Di Tomaso E, Sarr C, Trandafir L, Massacesi C, Eskens F, Bendell JC. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs 2014;32:670-81. [PMID: 24652201 DOI: 10.1007/s10637-014-0082-9] [Cited by in Crossref: 128] [Cited by in F6Publishing: 122] [Article Influence: 16.0] [Reference Citation Analysis]
124 Robinson D, Bertrand T, Carry J, Halley F, Karlsson A, Mathieu M, Minoux H, Perrin M, Robert B, Schio L, Sherman W. Differential Water Thermodynamics Determine PI3K-Beta/Delta Selectivity for Solvent-Exposed Ligand Modifications. J Chem Inf Model 2016;56:886-94. [DOI: 10.1021/acs.jcim.5b00641] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
125 Weigelt B, Warne PH, Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 2011;30:3222-33. [DOI: 10.1038/onc.2011.42] [Cited by in Crossref: 142] [Cited by in F6Publishing: 134] [Article Influence: 12.9] [Reference Citation Analysis]
126 Giordanetto F, Wållberg A, Ghosal S, Iliefski T, Cassel J, Yuan Z, von Wachenfeldt H, Andersen SM, Inghardt T, Tunek A, Nylander S. Discovery of phosphoinositide 3-kinases (PI3K) p110β isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance. Bioorganic & Medicinal Chemistry Letters 2012;22:6671-6. [DOI: 10.1016/j.bmcl.2012.08.102] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
127 Crumbaker M, Khoja L, Joshua AM. AR Signaling and the PI3K Pathway in Prostate Cancer. Cancers (Basel) 2017;9:E34. [PMID: 28420128 DOI: 10.3390/cancers9040034] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 14.6] [Reference Citation Analysis]
128 Ma CX, Crowder RJ, Ellis MJ. Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors. Steroids 2011;76:750-2. [PMID: 21420991 DOI: 10.1016/j.steroids.2011.02.023] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
129 Dbouk HA, Backer JM. Novel approaches to inhibitor design for the p110β phosphoinositide 3-kinase. Trends Pharmacol Sci 2013;34:149-53. [PMID: 23411347 DOI: 10.1016/j.tips.2012.12.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
130 Certal V, Halley F, Virone-oddos A, Filoche-rommé B, Carry J, Gruss-leleu F, Bertin L, Guizani H, Pilorge F, Richepin P, Karlsson A, Charrier V, Abecassis P, Vincent L, Nicolas J, Lengauer C, Garcia-echeverria C, Schio L. Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kβ inhibitors. Bioorganic & Medicinal Chemistry Letters 2014;24:1506-10. [DOI: 10.1016/j.bmcl.2014.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
131 Djordjevic B, Hennessy BT, Li J, Barkoh BA, Luthra R, Mills GB, Broaddus RR. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol. 2012;25:699-708. [PMID: 22301702 DOI: 10.1038/modpathol.2011.208] [Cited by in Crossref: 98] [Cited by in F6Publishing: 91] [Article Influence: 9.8] [Reference Citation Analysis]
132 Galli U, Ciraolo E, Massarotti A, Margaria JP, Sorba G, Hirsch E, Tron GC. The Guareschi Pyridine Scaffold as a Valuable Platform for the Identification of Selective PI3K Inhibitors. Molecules 2015;20:17275-87. [PMID: 26393561 DOI: 10.3390/molecules200917275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
133 Michaloglou C, Lehmann W, Martin T, Delaunay C, Hueber A, Barys L, Niu H, Billy E, Wartmann M, Ito M, Wilson CJ, Digan ME, Bauer A, Voshol H, Christofori G, Sellers WR, Hofmann F, Schmelzle T. The tyrosine phosphatase PTPN14 is a negative regulator of YAP activity. PLoS One 2013;8:e61916. [PMID: 23613971 DOI: 10.1371/journal.pone.0061916] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 6.7] [Reference Citation Analysis]
134 Miller MS, Thompson PE, Gabelli SB. Structural Determinants of Isoform Selectivity in PI3K Inhibitors. Biomolecules 2019;9:E82. [PMID: 30813656 DOI: 10.3390/biom9030082] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
135 Kubala MH, DeClerck YA. Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment. J Vis Exp 2017. [PMID: 29286360 DOI: 10.3791/56333] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
136 Simond AM, Rao T, Zuo D, Zhao JJ, Muller WJ. ErbB2-positive mammary tumors can escape PI3K-p110α loss through downregulation of the Pten tumor suppressor. Oncogene 2017;36:6059-66. [PMID: 28783168 DOI: 10.1038/onc.2017.264] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
137 Weigelt B, Warne PH, Lambros MB, Reis-Filho JS, Downward J. PI3K pathway dependencies in endometrioid endometrial cancer cell lines. Clin Cancer Res. 2013;19:3533-3544. [PMID: 23674493 DOI: 10.1158/1078-0432.ccr-12-3815] [Cited by in Crossref: 94] [Cited by in F6Publishing: 59] [Article Influence: 10.4] [Reference Citation Analysis]
138 Zhang H, Chen D, Ringler J, Chen W, Cui QC, Ethier SP, Dou QP, Wu G. Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. Cancer Res 2010;70:3996-4004. [PMID: 20424113 DOI: 10.1158/0008-5472.CAN-09-3752] [Cited by in Crossref: 59] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
139 Lord CJ, Quinn N, Ryan CJ. Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions. Elife 2020;9:e58925. [PMID: 32463358 DOI: 10.7554/eLife.58925] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
140 Xie C, Freeman MJ, Lu H, Wang X, Forster CL, Sarver AL, Hallstrom TC. Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235. Oncotarget 2017;8:38084-98. [PMID: 28445155 DOI: 10.18632/oncotarget.16970] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
141 Höland K, Boller D, Hagel C, Dolski S, Treszl A, Pardo OE, Cwiek P, Salm F, Leni Z, Shepherd PR, Styp-Rekowska B, Djonov V, von Bueren AO, Frei K, Arcaro A. Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma. PLoS One 2014;9:e94132. [PMID: 24718026 DOI: 10.1371/journal.pone.0094132] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
142 Yap TA, Bjerke L, Clarke PA, Workman P. Drugging PI3K in cancer: refining targets and therapeutic strategies. Curr Opin Pharmacol 2015;23:98-107. [PMID: 26117819 DOI: 10.1016/j.coph.2015.05.016] [Cited by in Crossref: 141] [Cited by in F6Publishing: 127] [Article Influence: 20.1] [Reference Citation Analysis]
143 Bregar AJ, Growdon WB. Emerging strategies for targeting PI3K in gynecologic cancer. Gynecol Oncol 2016;140:333-44. [PMID: 26432040 DOI: 10.1016/j.ygyno.2015.09.083] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
144 Kwon YM, Kim SH, Jung YS, Kwak JH. Synthesis and Biological Evaluation of (S)-2-(Substituted arylmethyl)-1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide Analogs and Their Synergistic Effect against PTEN-Deficient MDA-MB-468 Cells. Pharmaceuticals (Basel) 2021;14:974. [PMID: 34681198 DOI: 10.3390/ph14100974] [Reference Citation Analysis]
145 Wen FF, Wu SH, Li YY, Gao XQ, He S. Expression of PIK3CA, PIK3CB and proteins associated with multidrug resistance in colorectal carcinoma. Shijie Huaren Xiaohua Zazhi 2015; 23(2): 202-209 [DOI: 10.11569/wcjd.v23.i2.202] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
146 Burke JE. Structural Basis for Regulation of Phosphoinositide Kinases and Their Involvement in Human Disease. Molecular Cell 2018;71:653-73. [DOI: 10.1016/j.molcel.2018.08.005] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 19.3] [Reference Citation Analysis]
147 Kwan EM, Dai C, Fettke H, Hauser C, Docanto MM, Bukczynska P, Ng N, Foroughi S, Graham LK, Mahon K, Tan W, Wang X, Zhao Z, Zheng T, Zhou K, Yu J, Du P, Horvath LG, Jia S, Kohli M, Azad AA. Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol 2021;5:PO. [PMID: 34250422 DOI: 10.1200/PO.20.00424] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
148 Stratikopoulos EE, Dendy M, Szabolcs M, Khaykin AJ, Lefebvre C, Zhou MM, Parsons R. Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy. Cancer Cell 2015;27:837-51. [PMID: 26058079 DOI: 10.1016/j.ccell.2015.05.006] [Cited by in Crossref: 146] [Cited by in F6Publishing: 132] [Article Influence: 20.9] [Reference Citation Analysis]
149 González-Cao M, Rodón J, Karachaliou N, Sánchez J, Santarpia M, Viteri S, Pilotto S, Teixidó C, Riso A, Rosell R. Other targeted drugs in melanoma. Ann Transl Med 2015;3:266. [PMID: 26605312 DOI: 10.3978/j.issn.2305-5839.2015.08.12] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
150 Utermark T, Rao T, Cheng H, Wang Q, Lee SH, Wang ZC, Iglehart JD, Roberts TM, Muller WJ, Zhao JJ. The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev. 2012;26:1573-1586. [PMID: 22802530 DOI: 10.1101/gad.191973.112] [Cited by in Crossref: 93] [Cited by in F6Publishing: 96] [Article Influence: 9.3] [Reference Citation Analysis]
151 Bédard PL, Davies MA, Kopetz S, Juric D, Shapiro GI, Luke JJ, Spreafico A, Wu B, Castell C, Gomez C, Cartot-Cotton S, Mazuir F, Dubar M, Micallef S, Demers B, Flaherty KT. First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors. Cancer 2018;124:315-24. [PMID: 28976556 DOI: 10.1002/cncr.31044] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
152 Mazloumi Gavgani F, Karlsson T, Tangen IL, Morovicz AP, Arnesen VS, Turcu DC, Ninzima S, Spang K, Krakstad C, Guillermet-Guibert J, Lewis AE. Nuclear upregulation of class I phosphoinositide 3-kinase p110β correlates with high 47S rRNA levels in cancer cells. J Cell Sci 2021;134:jcs246090. [PMID: 33536247 DOI: 10.1242/jcs.246090] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
153 Shibata T, Kokubu A, Tsuta K, Hirohashi S. Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer. Cancer Lett 2009;283:203-11. [PMID: 19394761 DOI: 10.1016/j.canlet.2009.03.038] [Cited by in Crossref: 33] [Cited by in F6Publishing: 42] [Article Influence: 2.5] [Reference Citation Analysis]
154 Sethi I, Cai Z, Roberts TM, Yuan GC. Molecular Profiling Establishes Genetic Features Predictive of the Efficacy of the p110β Inhibitor KIN-193. Cancer Res 2019;79:4524-31. [PMID: 31292159 DOI: 10.1158/0008-5472.CAN-19-0588] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
155 Huang WS, Wang TB, He Y, Chen YJ, Zhong SL, Tan M. Phosphoinositide-3-kinase, catalytic, alpha polypeptide RNA interference inhibits growth of colon cancer cell SW948. World J Gastroenterol 2012; 18(26): 3458-3464 [PMID: 22807617 DOI: 10.3748/wjg.v18.i26.3458] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
156 Aoki M, Fujishita T. Oncogenic Roles of the PI3K/AKT/mTOR Axis. Curr Top Microbiol Immunol 2017;407:153-89. [PMID: 28550454 DOI: 10.1007/82_2017_6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 70] [Article Influence: 10.7] [Reference Citation Analysis]
157 Brana I, Pham NA, Kim L, Sakashita S, Li M, Ng C, Wang Y, Loparco P, Sierra R, Wang L, Clarke BA, Neel BG, Siu LL, Tsao MS. Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts. Oncotarget 2017;8:84659-70. [PMID: 29156674 DOI: 10.18632/oncotarget.19109] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
158 Janus JM, O'Shaughnessy RFL, Harwood CA, Maffucci T. Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas. Cancers (Basel) 2017;9:E86. [PMID: 28696382 DOI: 10.3390/cancers9070086] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
159 Zhao W, Qiu Y, Kong D. Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy. Acta Pharm Sin B. 2017;7:27-37. [PMID: 28119806 DOI: 10.1016/j.apsb.2016.07.006] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 12.3] [Reference Citation Analysis]
160 Pons-tostivint E, Thibault B, Guillermet-guibert J. Targeting PI3K Signaling in Combination Cancer Therapy. Trends in Cancer 2017;3:454-69. [DOI: 10.1016/j.trecan.2017.04.002] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 15.0] [Reference Citation Analysis]
161 Beishline K, Kelly CM, Olofsson BA, Koduri S, Emrich J, Greenberg RA, Azizkhan-Clifford J. Sp1 facilitates DNA double-strand break repair through a nontranscriptional mechanism. Mol Cell Biol 2012;32:3790-9. [PMID: 22826432 DOI: 10.1128/MCB.00049-12] [Cited by in Crossref: 37] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
162 Pugacheva EM, Teplyakov E, Wu Q, Li J, Chen C, Meng C, Liu J, Robinson S, Loukinov D, Boukaba A, Hutchins AP, Lobanenkov V, Strunnikov A. The cancer-associated CTCFL/BORIS protein targets multiple classes of genomic repeats, with a distinct binding and functional preference for humanoid-specific SVA transposable elements. Epigenetics Chromatin 2016;9:35. [PMID: 27588042 DOI: 10.1186/s13072-016-0084-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
163 Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, Wong KK, Cantley LC, Engelman JA. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest 2011;121:4311-21. [PMID: 21985784 DOI: 10.1172/JCI57909] [Cited by in Crossref: 149] [Cited by in F6Publishing: 106] [Article Influence: 13.5] [Reference Citation Analysis]
164 Karlsson T, Krakstad C, Tangen IL, Hoivik EA, Pollock PM, Salvesen HB, Lewis AE. Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. Oncotarget 2017;8:3881-94. [PMID: 28002804 DOI: 10.18632/oncotarget.13989] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
165 Barlaam B, Cosulich S, Degorce S, Fitzek M, Green S, Hancox U, Lambert-van der Brempt C, Lohmann JJ, Maudet M, Morgentin R, Péru A, Plé P, Saleh T, Ward L, Warin N. Discovery of a series of 8-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-2-morpholino-4-oxo-chromene-6-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours. Bioorg Med Chem Lett 2016;26:2318-23. [PMID: 26996374 DOI: 10.1016/j.bmcl.2016.03.034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
166 Bowles DW, Ma WW, Senzer N, Brahmer JR, Adjei AA, Davies M, Lazar AJ, Vo A, Peterson S, Walker L, Hausman D, Rudin CM, Jimeno A. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br J Cancer 2013;109:1085-92. [PMID: 23942080 DOI: 10.1038/bjc.2013.474] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
167 Whale AD, Colman L, Lensun L, Rogers HL, Shuttleworth SJ. Functional characterization of a novel somatic oncogenic mutation of PIK3CB. Signal Transduct Target Ther 2017;2:17063. [PMID: 29279775 DOI: 10.1038/sigtrans.2017.63] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
168 Scott WJ, Hentemann MF, Rowley RB, Bull CO, Jenkins S, Bullion AM, Johnson J, Redman A, Robbins AH, Esler W, Fracasso RP, Garrison T, Hamilton M, Michels M, Wood JE, Wilkie DP, Xiao H, Levy J, Stasik E, Liu N, Schaefer M, Brands M, Lefranc J. Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946). ChemMedChem 2016;11:1517-30. [PMID: 27310202 DOI: 10.1002/cmdc.201600148] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 8.2] [Reference Citation Analysis]
169 Gross C. Defective phosphoinositide metabolism in autism. J Neurosci Res 2017;95:1161-73. [PMID: 27376697 DOI: 10.1002/jnr.23797] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
170 Millán-Uclés Á, Zuluaga S, Marqués M, Vallejo-Díaz J, Sanz L, Cariaga-Martínez AE, Real FX, Carrera AC. E-cadherin downregulation sensitizes PTEN-mutant tumors to PI3Kβ silencing. Oncotarget 2016;7:84054-71. [PMID: 27863432 DOI: 10.18632/oncotarget.13414] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
171 Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013;10:143-53. [DOI: 10.1038/nrclinonc.2013.10] [Cited by in Crossref: 521] [Cited by in F6Publishing: 481] [Article Influence: 57.9] [Reference Citation Analysis]
172 Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, Meissner B, Bhang HE, Ruddy D, Kauffmann A, Farsidjani A, Derti A, Rakiec D, Naylor T, Pfister E, Kovats S, Kim S, Dietze K, Dörken B, Steidl C, Tzankov A, Hummel M, Monahan J, Morrissey MP, Fritsch C, Sellers WR, Cooke VG, Gascoyne RD, Lenz G, Stegmeier F. Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma. Nat Med 2014;20:87-92. [PMID: 24362935 DOI: 10.1038/nm.3435] [Cited by in Crossref: 201] [Cited by in F6Publishing: 200] [Article Influence: 22.3] [Reference Citation Analysis]
173 Xu PF, Yang JA, Liu JH, Yang X, Liao JM, Yuan FE, Liu BH, Chen QX. PI3Kβ inhibitor AZD6482 exerts antiproliferative activity and induces apoptosis in human glioblastoma cells. Oncol Rep 2019;41:125-32. [PMID: 30542720 DOI: 10.3892/or.2018.6845] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
174 Bourquin JP, Izraeli S. Where can biology of childhood ALL be attacked by new compounds? Cancer Treat Rev 2010;36:298-306. [PMID: 20223597 DOI: 10.1016/j.ctrv.2010.02.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
175 Maira SM, Furet P, Stauffer F. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway. Future Med Chem 2009;1:137-55. [PMID: 21426073 DOI: 10.4155/fmc.09.5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
176 Tang YC, Ho SC, Tan E, Ng AWT, McPherson JR, Goh GYL, Teh BT, Bard F, Rozen SG. Functional genomics identifies specific vulnerabilities in PTEN-deficient breast cancer. Breast Cancer Res 2018;20:22. [PMID: 29566768 DOI: 10.1186/s13058-018-0949-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
177 Schlienger S, Campbell S, Pasquin S, Gaboury L, Claing A. ADP-ribosylation factor 1 expression regulates epithelial-mesenchymal transition and predicts poor clinical outcome in triple-negative breast cancer. Oncotarget 2016;7:15811-27. [PMID: 26908458 DOI: 10.18632/oncotarget.7515] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
178 Arcucci S, Ramos-delgado F, Cayron C, Therville N, Gratacap M, Basset C, Thibault B, Guillermet-guibert J. Organismal roles for the PI3Kα and β isoforms: their specificity, redundancy or cooperation is context-dependent. Biochemical Journal 2021;478:1199-225. [DOI: 10.1042/bcj20210004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
179 Barlaam B, Cosulich S, Degorce S, Ellston R, Fitzek M, Green S, Hancox U, Lambert-van der Brempt C, Lohmann JJ, Maudet M, Morgentin R, Plé P, Ward L, Warin N. Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4H-chromen-4-one as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours. Bioorg Med Chem Lett 2017;27:1949-54. [PMID: 28347666 DOI: 10.1016/j.bmcl.2017.03.027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
180 Salloum G, Jakubik CT, Erami Z, Heitz SD, Bresnick AR, Backer JM. PI3Kβ is selectively required for growth factor-stimulated macropinocytosis. J Cell Sci 2019;132:jcs231639. [PMID: 31409694 DOI: 10.1242/jcs.231639] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
181 Alekseev O, Limonnik V, Donovan K, Azizkhan-Clifford J. Activation of checkpoint kinase 2 is critical for herpes simplex virus type 1 replication in corneal epithelium. Ophthalmic Res 2015;53:55-64. [PMID: 25531207 DOI: 10.1159/000366228] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
182 Bočkaj I, Martini TEI, de Camargo Magalhães ES, Bakker PL, Meeuwsen-de Boer TGJ, Armandari I, Meuleman SL, Mondria MT, Stok C, Kok YP, Bakker B, Wardenaar R, Seiler J, Broekhuis MJC, van den Bos H, Spierings DCJ, Ringnalda FCA, Clevers H, Schüller U, van Vugt MATM, Foijer F, Bruggeman SWM. The H3.3K27M oncohistone affects replication stress outcome and provokes genomic instability in pediatric glioma. PLoS Genet 2021;17:e1009868. [PMID: 34752469 DOI: 10.1371/journal.pgen.1009868] [Reference Citation Analysis]
183 Dong C, Wu J, Chen Y, Nie J, Chen C. Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. Front Pharmacol 2021;12:628690. [PMID: 33790792 DOI: 10.3389/fphar.2021.628690] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
184 Leng C, Zhang Z, Chen W, Luo H, Song J, Dong W, Zhu X, Chen X, Liang H, Zhang B. An integrin beta4-EGFR unit promotes hepatocellular carcinoma lung metastases by enhancing anchorage independence through activation of FAK–AKT pathway. Cancer Letters 2016;376:188-96. [DOI: 10.1016/j.canlet.2016.03.023] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
185 Certal V, Halley F, Virone-Oddos A, Delorme C, Karlsson A, Rak A, Thompson F, Filoche-Rommé B, El-Ahmad Y, Carry JC, Abecassis PY, Lejeune P, Vincent L, Bonnevaux H, Nicolas JP, Bertrand T, Marquette JP, Michot N, Benard T, Below P, Vade I, Chatreaux F, Lebourg G, Pilorge F, Angouillant-Boniface O, Louboutin A, Lengauer C, Schio L. Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers. J Med Chem 2012;55:4788-805. [PMID: 22524426 DOI: 10.1021/jm300241b] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
186 Kawada H, Ebiike H, Tsukazaki M, Yamamoto S, Koyama K, Nakamura M, Morikami K, Yoshinari K, Yoshida M, Ogawa K, Shimma N, Tsukuda T, Ohwada J. Optimization of the phenylurea moiety in a phosphoinositide 3-kinase (PI3K) inhibitor to improve water solubility and the PK profile by introducing a solubilizing group and ortho substituents. Bioorganic & Medicinal Chemistry 2016;24:2897-906. [DOI: 10.1016/j.bmc.2016.04.060] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
187 Braglia L, Zavatti M, Vinceti M, Martelli AM, Marmiroli S. Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target? Biochim Biophys Acta Mol Cell Res 2020;1867:118731. [PMID: 32360668 DOI: 10.1016/j.bbamcr.2020.118731] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
188 Wang Q, Li Y, Cheng J, Chen L, Xu H, Li Q, Pang T. Sam68 affects cell proliferation and apoptosis of human adult T-acute lymphoblastic leukemia cells via AKT/mTOR signal pathway. Leukemia Research 2016;46:1-9. [DOI: 10.1016/j.leukres.2016.04.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
189 Ito Y, Hart JR, Vogt PK. Isoform-specific activities of the regulatory subunits of phosphatidylinositol 3-kinases - potentially novel therapeutic targets. Expert Opin Ther Targets 2018;22:869-77. [PMID: 30205700 DOI: 10.1080/14728222.2018.1522302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
190 Chroma K, Mistrik M, Moudry P, Gursky J, Liptay M, Strauss R, Skrott Z, Vrtel R, Bartkova J, Kramara J, Bartek J. Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress. Oncogene 2017;36:2405-22. [DOI: 10.1038/onc.2016.392] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
191 Lu X, Ciraolo E, Stefenia R, Chen G, Zhang Y, Hirsch E. Sustained release of PI3K inhibitor from PHA nanoparticles and in vitro growth inhibition of cancer cell lines. Appl Microbiol Biotechnol 2011;89:1423-33. [DOI: 10.1007/s00253-011-3101-1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
192 Lin H, Erhard K, Hardwicke MA, Luengo JI, Mack JF, Mcsurdy-freed J, Plant R, Raha K, Rominger CM, Sanchez RM, Schaber MD, Schulz MJ, Spengler MD, Tedesco R, Xie R, Zeng JJ, Rivero RA. Synthesis and structure–activity relationships of imidazo[1,2-a]pyrimidin-5(1H)-ones as a novel series of beta isoform selective phosphatidylinositol 3-kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 2012;22:2230-4. [DOI: 10.1016/j.bmcl.2012.01.092] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
193 Garcia-Albornoz M, Nielsen J. Finding directionality and gene-disease predictions in disease associations. BMC Syst Biol 2015;9:35. [PMID: 26168918 DOI: 10.1186/s12918-015-0184-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
194 Karvonen H, Perttilä R, Niininen W, Hautanen V, Barker H, Murumägi A, Heckman CA, Ungureanu D. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting. Oncogene 2019;38:3288-300. [PMID: 30631148 DOI: 10.1038/s41388-018-0670-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
195 Certal V, Carry J, Halley F, Virone-oddos A, Thompson F, Filoche-rommé B, El-ahmad Y, Karlsson A, Charrier V, Delorme C, Rak A, Abecassis P, Amara C, Vincent L, Bonnevaux H, Nicolas J, Mathieu M, Bertrand T, Marquette J, Michot N, Benard T, Perrin M, Lemaitre O, Guerif S, Perron S, Monget S, Gruss-leleu F, Doerflinger G, Guizani H, Brollo M, Delbarre L, Bertin L, Richepin P, Loyau V, Garcia-echeverria C, Lengauer C, Schio L. Discovery and Optimization of Pyrimidone Indoline Amide PI3Kβ Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers. J Med Chem 2014;57:903-20. [DOI: 10.1021/jm401642q] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
196 Tzenaki N, Papakonstanti EA. p110δ PI3 kinase pathway: emerging roles in cancer. Front Oncol 2013;3:40. [PMID: 23459844 DOI: 10.3389/fonc.2013.00040] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
197 Shehata M, Schnabl S, Demirtas D, Hilgarth M, Hubmann R, Ponath E, Badrnya S, Lehner C, Hoelbl A, Duechler M, Gaiger A, Zielinski C, Schwarzmeier JD, Jaeger U. Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia. Blood 2010;116:2513-21. [PMID: 20576813 DOI: 10.1182/blood-2009-10-248054] [Cited by in Crossref: 82] [Cited by in F6Publishing: 75] [Article Influence: 6.8] [Reference Citation Analysis]
198 Guillermet-Guibert J, Smith LB, Halet G, Whitehead MA, Pearce W, Rebourcet D, León K, Crépieux P, Nock G, Strömstedt M, Enerback M, Chelala C, Graupera M, Carroll J, Cosulich S, Saunders PT, Huhtaniemi I, Vanhaesebroeck B. Novel Role for p110β PI 3-Kinase in Male Fertility through Regulation of Androgen Receptor Activity in Sertoli Cells. PLoS Genet 2015;11:e1005304. [PMID: 26132308 DOI: 10.1371/journal.pgen.1005304] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
199 Allen CE, Laetsch TW, Mody R, Irwin MS, Lim MS, Adamson PC, Seibel NL, Parsons DW, Cho YJ, Janeway K; Pediatric MATCH Target and Agent Prioritization Committee. Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial. J Natl Cancer Inst 2017;109. [PMID: 28376230 DOI: 10.1093/jnci/djw274] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 8.4] [Reference Citation Analysis]
200 Singh P, Dar MS, Dar MJ. p110α and p110β isoforms of PI3K signaling: are they two sides of the same coin? FEBS Lett 2016;590:3071-82. [PMID: 27552098 DOI: 10.1002/1873-3468.12377] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
201 Stratikopoulos EE, Parsons RE. Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue. Clin Cancer Res 2016;22:2605-10. [PMID: 27250929 DOI: 10.1158/1078-0432.CCR-15-2389] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
202 Takiar V, Ip CK, Gao M, Mills GB, Cheung LW. Neomorphic mutations create therapeutic challenges in cancer. Oncogene 2017;36:1607-18. [PMID: 27841866 DOI: 10.1038/onc.2016.312] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
203 Hill KM, Kalifa S, Das JR, Bhatti T, Gay M, Williams D, Taliferro-Smith L, De Marzo AM. The role of PI 3-kinase p110beta in AKT signally, cell survival, and proliferation in human prostate cancer cells. Prostate 2010;70:755-64. [PMID: 20058239 DOI: 10.1002/pros.21108] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
204 Sasaki T, Takasuga S, Sasaki J, Kofuji S, Eguchi S, Yamazaki M, Suzuki A. Mammalian phosphoinositide kinases and phosphatases. Prog Lipid Res 2009;48:307-43. [PMID: 19580826 DOI: 10.1016/j.plipres.2009.06.001] [Cited by in Crossref: 167] [Cited by in F6Publishing: 147] [Article Influence: 12.8] [Reference Citation Analysis]
205 Kwong LN, Davies MA. Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma. Clin Cancer Res 2013;19:5310-9. [PMID: 24089444 DOI: 10.1158/1078-0432.CCR-13-0142] [Cited by in Crossref: 60] [Cited by in F6Publishing: 39] [Article Influence: 7.5] [Reference Citation Analysis]
206 Kong D, Zhang Y, Yamori T, Duan H, Jin M. Inhibitory activity of flavonoids against class I phosphatidylinositol 3-kinase isoforms. Molecules 2011;16:5159-67. [PMID: 21694679 DOI: 10.3390/molecules16065159] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
207 Joshi A, Miller C Jr, Baker SJ, Ellenson LH. Activated mutant p110α causes endometrial carcinoma in the setting of biallelic Pten deletion. Am J Pathol 2015;185:1104-13. [PMID: 25698082 DOI: 10.1016/j.ajpath.2014.12.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
208 Lin H, Schulz MJ, Xie R, Zeng J, Luengo JI, Squire MD, Tedesco R, Qu J, Erhard K, Mack JF, Raha K, Plant R, Rominger CM, Ariazi JL, Sherk CS, Schaber MD, McSurdy-Freed J, Spengler MD, Davis CB, Hardwicke MA, Rivero RA. Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors. ACS Med Chem Lett 2012;3:524-9. [PMID: 24900504 DOI: 10.1021/ml300045b] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
209 Park S, Kim YS, Kim DY, So I, Jeon J. PI3K pathway in prostate cancer: All resistant roads lead to PI3K. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2018;1870:198-206. [DOI: 10.1016/j.bbcan.2018.09.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
210 So L, Yea SS, Oak JS, Lu M, Manmadhan A, Ke QH, Janes MR, Kessler LV, Kucharski JM, Li LS, Martin MB, Ren P, Jessen KA, Liu Y, Rommel C, Fruman DA. Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function. J Biol Chem 2013;288:5718-31. [PMID: 23275335 DOI: 10.1074/jbc.M112.379446] [Cited by in Crossref: 50] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
211 Ros S, Wright AJ, D'Santos P, Hu DE, Hesketh RL, Lubling Y, Georgopoulou D, Lerda G, Couturier DL, Razavi P, Pelossof R, Batra AS, Mannion E, Lewis DY, Martin A, Baird RD, Oliveira M, de Boo LW, Linn SC, Scaltriti M, Rueda OM, Bruna A, Caldas C, Brindle KM. Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer. Cancer Cell 2020;38:516-533.e9. [PMID: 32976773 DOI: 10.1016/j.ccell.2020.08.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
212 Chakraborty S, Balan M, Sabarwal A, Choueiri TK, Pal S. Metabolic reprogramming in renal cancer: Events of a metabolic disease. Biochim Biophys Acta Rev Cancer 2021;1876:188559. [PMID: 33965513 DOI: 10.1016/j.bbcan.2021.188559] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
213 Ferguson MS, Lemoine NR, Wang Y. Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol. 2012;2012:805629. [PMID: 22400027 DOI: 10.1155/2012/805629] [Cited by in Crossref: 104] [Cited by in F6Publishing: 101] [Article Influence: 10.4] [Reference Citation Analysis]
214 Carvalho S, Schmitt F. Potential role of PI3K inhibitors in the treatment of breast cancer. Future Oncology 2010;6:1251-63. [DOI: 10.2217/fon.10.97] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
215 Li Y, Bakke J, Finkelstein D, Zeng H, Wu J, Chen T. HNRNPH1 is required for rhabdomyosarcoma cell growth and survival. Oncogenesis 2018;7:9. [PMID: 29362363 DOI: 10.1038/s41389-017-0024-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
216 Lee SH, Poulogiannis G, Pyne S, Jia S, Zou L, Signoretti S, Loda M, Cantley LC, Roberts TM. A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. Proc Natl Acad Sci U S A 2010;107:11002-7. [PMID: 20534477 DOI: 10.1073/pnas.1005642107] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
217 Zheng Z, Miller MS, Jennings IG, Thompson PE. Mechanisms of PI3Kβ-Selective Inhibition Revealed by Reciprocal Mutagenesis. ACS Chem Biol 2013;8:679-83. [DOI: 10.1021/cb300666s] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
218 Yu H, Moore ML, Erhard K, Hardwicke MA, Lin H, Luengo JI, McSurdy-Freed J, Plant R, Qu J, Raha K, Rominger CM, Schaber MD, Spengler MD, Rivero RA. [3a,4]-Dihydropyrazolo[1,5a]pyrimidines: Novel, Potent, and Selective Phosphatidylinositol-3-kinase β Inhibitors. ACS Med Chem Lett 2013;4:230-4. [PMID: 24900655 DOI: 10.1021/ml300330m] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
219 Schwarzenbacher D, Klec C, Pasculli B, Cerk S, Rinner B, Karbiener M, Ivan C, Barbano R, Ling H, Wulf-Goldenberg A, Stanzer S, Rinnerthaler G, Stoeger H, Bauernhofer T, Haybaeck J, Hoefler G, Jahn SW, Parrella P, Calin GA, Pichler M. MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors. Breast Cancer Res 2019;21:20. [PMID: 30709367 DOI: 10.1186/s13058-019-1104-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
220 Kim HS, Mitsudomi T, Soo RA, Cho BC. Personalized therapy on the horizon for squamous cell carcinoma of the lung. Lung Cancer 2013;80:249-55. [PMID: 23489560 DOI: 10.1016/j.lungcan.2013.02.015] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 4.6] [Reference Citation Analysis]
221 Lv J, Su J, Wang F, Qi Y, Liu H, Zhang Y. Detecting novel hypermethylated genes in breast cancer benefiting from feature selection. Comput Biol Med 2010;40:159-67. [PMID: 20044084 DOI: 10.1016/j.compbiomed.2009.11.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
222 Yiu GK, Kaunisto A, Chin YR, Toker A. NFAT promotes carcinoma invasive migration through glypican-6. Biochem J. 2011;440:157-166. [PMID: 21871017 DOI: 10.1042/bj20110530] [Cited by in Crossref: 65] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
223 Khan MI, Al Johani A, Hamid A, Ateeq B, Manzar N, Adhami VM, Lall RK, Rath S, Sechi M, Siddiqui IA, Choudhry H, Zamzami MA, Havighurst TC, Huang W, Ntambi JM, Mukhtar H. Proproliferative function of adaptor protein GRB10 in prostate carcinoma. FASEB J 2019;33:3198-211. [PMID: 30379590 DOI: 10.1096/fj.201800265RR] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
224 Fransecky L, Mochmann LH, Baldus CD. Outlook on PI3K/AKT/mTOR inhibition in acute leukemia. Mol Cell Ther. 2015;3:2. [PMID: 26056603 DOI: 10.1186/s40591-015-0040-8] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 10.6] [Reference Citation Analysis]
225 El Motiam A, de la Cruz-Herrera CF, Vidal S, Seoane R, Baz-Martínez M, Bouzaher YH, Lecona E, Esteban M, Rodríguez MS, Vidal A, Collado M, Rivas C. SUMOylation modulates the stability and function of PI3K-p110β. Cell Mol Life Sci 2021;78:4053-65. [PMID: 33834259 DOI: 10.1007/s00018-021-03826-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
226 Beadnell TC, Nassar KW, Rose MM, Clark EG, Danysh BP, Hofmann MC, Pozdeyev N, Schweppe RE. Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer. Oncogenesis 2018;7:23. [PMID: 29487290 DOI: 10.1038/s41389-017-0015-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
227 Hyman DM, Snyder AE, Carvajal RD, Gerecitano JF, Voss MH, Ho AL, Konner J, Winkelmann JL, Stasi MA, Monson KR, Iasonos A, Spriggs DR, Bialer P, Lacouture ME, Teitcher JB, Katabi N, Fury MG. Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. Cancer Chemother Pharmacol 2015;75:747-55. [PMID: 25672916 DOI: 10.1007/s00280-015-2693-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
228 Tran KB, Kolekar S, Jabed A, Jaynes P, Shih JH, Wang Q, Flanagan JU, Rewcastle GW, Baguley BC, Shepherd PR. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK. BMC Cancer 2021;21:136. [PMID: 33549048 DOI: 10.1186/s12885-021-07826-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
229 Papadatos-Pastos D, Rabbie R, Ross P, Sarker D. The role of the PI3K pathway in colorectal cancer. Crit Rev Oncol Hematol. 2015;94:18-30. [PMID: 25591826 DOI: 10.1016/j.critrevonc.2014.12.006] [Cited by in Crossref: 44] [Cited by in F6Publishing: 51] [Article Influence: 5.5] [Reference Citation Analysis]
230 Deuker MM, Marsh Durban V, Phillips WA, McMahon M. PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Cancer Discov 2015;5:143-53. [PMID: 25472943 DOI: 10.1158/2159-8290.CD-14-0856] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
231 Mao N, Zhang Z, Lee YS, Choi D, Rivera AA, Li D, Lee C, Haywood S, Chen X, Chang Q, Xu G, Chen HA, de Stanchina E, Sawyers C, Rosen N, Hsieh AC, Chen Y, Carver BS. Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers. Nat Commun 2021;12:5053. [PMID: 34417459 DOI: 10.1038/s41467-021-25341-9] [Reference Citation Analysis]
232 Brandão M, Caparica R, Eiger D, de Azambuja E. Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. Ann Oncol 2019;30 Suppl 10:x27-42. [PMID: 31928692 DOI: 10.1093/annonc/mdz280] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 14.5] [Reference Citation Analysis]
233 Dbouk HA, Backer JM. A beta version of life: p110β takes center stage. Oncotarget 2010;1:729-33. [PMID: 21321382 DOI: 10.18632/oncotarget.101205] [Cited by in F6Publishing: 24] [Reference Citation Analysis]
234 Lee HJ, Venkatarame Gowda Saralamma V, Kim SM, Ha SE, Vetrivel P, Kim EH, Lee SJ, Heo JD, Rampogu S, Lee KW, Kim GS. Comparative Proteomic Profiling of Tumor-Associated Proteins in Human Gastric Cancer Cells Treated with Pectolinarigenin. Nutrients 2018;10:E1596. [PMID: 30380781 DOI: 10.3390/nu10111596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
235 Tamborero D, Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Kandoth C, Reimand J, Lawrence MS, Getz G, Bader GD, Ding L. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep. 2013;3:2650. [PMID: 24084849 DOI: 10.1038/srep02650] [Cited by in Crossref: 316] [Cited by in F6Publishing: 290] [Article Influence: 35.1] [Reference Citation Analysis]
236 Zhao Y, Karijolich J, Glaunsinger B, Zhou Q. Pseudouridylation of 7SK snRNA promotes 7SK snRNP formation to suppress HIV-1 transcription and escape from latency. EMBO Rep 2016;17:1441-51. [PMID: 27558685 DOI: 10.15252/embr.201642682] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
237 Lynch JT, McEwen R, Crafter C, McDermott U, Garnett MJ, Barry ST, Davies BR. Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen. Oncotarget 2016;7:22128-39. [PMID: 26989080 DOI: 10.18632/oncotarget.8031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
238 Stamatkin C, Ratermann KL, Overley CW, Black EP. Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms. Cancer Biol Ther 2015;16:1341-52. [PMID: 26176612 DOI: 10.1080/15384047.2015.1070986] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
239 Brachmann S, Fritsch C, Maira SM, García-Echeverría C. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. Curr Opin Cell Biol. 2009;21:194-198. [PMID: 19201591 DOI: 10.1016/j.ceb.2008.12.011] [Cited by in Crossref: 88] [Cited by in F6Publishing: 82] [Article Influence: 6.8] [Reference Citation Analysis]
240 Dbouk HA, Vadas O, Shymanets A, Burke JE, Salamon RS, Khalil BD, Barrett MO, Waldo GL, Surve C, Hsueh C, Perisic O, Harteneck C, Shepherd PR, Harden TK, Smrcka AV, Taussig R, Bresnick AR, Nürnberg B, Williams RL, Backer JM. G protein-coupled receptor-mediated activation of p110β by Gβγ is required for cellular transformation and invasiveness. Sci Signal 2012;5:ra89. [PMID: 23211529 DOI: 10.1126/scisignal.2003264] [Cited by in Crossref: 99] [Cited by in F6Publishing: 94] [Article Influence: 9.9] [Reference Citation Analysis]
241 Cheng H, Aplin AE. Game of isoforms: PI3K β-sparing inhibitor is coming. Pigment Cell Melanoma Res 2015;28:133-4. [PMID: 25573297 DOI: 10.1111/pcmr.12350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
242 Xenou L, Papakonstanti E. p110δ PI3K as a therapeutic target of solid tumours. Clinical Science 2020;134:1377-97. [DOI: 10.1042/cs20190772] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
243 Fransson S, Kogner P, Martinsson T, Ejeskär K. Aggressive neuroblastomas have high p110alpha but low p110delta and p55alpha/p50alpha protein levels compared to low stage neuroblastomas. J Mol Signal 2013;8:4. [PMID: 23597230 DOI: 10.1186/1750-2187-8-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
244 Bradford LS, Rauh-Hain A, Clark RM, Groeneweg JW, Zhang L, Borger D, Zukerberg LR, Growdon WB, Foster R, Rueda BR. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer. Gynecol Oncol 2014;133:346-52. [PMID: 24561032 DOI: 10.1016/j.ygyno.2014.02.022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
245 White AR, Tiwari D, MacLeod MC, Danzer SC, Gross C. PI3K isoform-selective inhibition in neuron-specific PTEN-deficient mice rescues molecular defects and reduces epilepsy-associated phenotypes. Neurobiol Dis 2020;144:105026. [PMID: 32712265 DOI: 10.1016/j.nbd.2020.105026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
246 Wang J, Lv X, Guo X, Dong Y, Peng P, Huang F, Wang P, Zhang H, Zhou J, Wang Y, Wei B, Shang ZF, Li S. Feedback activation of STAT3 limits the response to PI3K/AKT/mTOR inhibitors in PTEN-deficient cancer cells. Oncogenesis 2021;10:8. [PMID: 33431808 DOI: 10.1038/s41389-020-00292-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
247 Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS One 2012;7:e37431. [PMID: 22662154 DOI: 10.1371/journal.pone.0037431] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
248 Hernández G, Ramírez JL, Pedroza-Torres A, Herrera LA, Jiménez-Ríos MA. The Secret Life of Translation Initiation in Prostate Cancer. Front Genet 2019;10:14. [PMID: 30761182 DOI: 10.3389/fgene.2019.00014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
249 Jamieson S, Flanagan JU, Kolekar S, Buchanan C, Kendall JD, Lee WJ, Rewcastle GW, Denny WA, Singh R, Dickson J. A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J. 2011;438:53-62. [PMID: 21668414 DOI: 10.1042/BJ20110502] [Cited by in Crossref: 120] [Cited by in F6Publishing: 70] [Article Influence: 10.9] [Reference Citation Analysis]
250 Dbouk HA, Vadas O, Williams RL, Backer JM. PI3Kβ downstream of GPCRs - crucial partners in oncogenesis. Oncotarget 2012;3:1485-6. [PMID: 23328076 DOI: 10.18632/oncotarget.787] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
251 Berenjeno IM, Guillermet-Guibert J, Pearce W, Gray A, Fleming S, Vanhaesebroeck B. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor. Biochem J 2012;442:151-9. [PMID: 22150431 DOI: 10.1042/BJ20111741] [Cited by in Crossref: 49] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
252 Balla T. Phosphoinositides: tiny lipids with giant impact on cell regulation. Physiol Rev. 2013;93:1019-1137. [PMID: 23899561 DOI: 10.1152/physrev.00028.2012] [Cited by in Crossref: 875] [Cited by in F6Publishing: 790] [Article Influence: 97.2] [Reference Citation Analysis]
253 Neuhausen SL, Brummel S, Ding YC, Steele L, Nathanson KL, Domchek S, Rebbeck TR, Singer CF, Pfeiler G, Lynch HT, Garber JE, Couch F, Weitzel JN, Godwin A, Narod SA, Ganz PA, Daly MB, Isaacs C, Olopade OI, Tomlinson GE, Rubinstein WS, Tung N, Blum JL, Gillen DL. Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. Cancer Epidemiol Biomarkers Prev 2011;20:1690-702. [PMID: 21708937 DOI: 10.1158/1055-9965.EPI-10-1336] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
254 Ariyama J, Suyama M, Ogawa K, Ikari T, Nagaiwa J, Fujii D, Tsuchida A. The detection and prognosis of small pancreatic carcinoma. Int J Pancreatol. 1990;7:37-47. [PMID: 1964473 DOI: 10.1038/nrd2926] [Cited by in Crossref: 1691] [Cited by in F6Publishing: 1605] [Article Influence: 54.5] [Reference Citation Analysis]
255 Castellino RC, Barwick BG, Schniederjan M, Buss MC, Becher O, Hambardzumyan D, Macdonald TJ, Brat DJ, Durden DL. Heterozygosity for Pten promotes tumorigenesis in a mouse model of medulloblastoma. PLoS One 2010;5:e10849. [PMID: 20520772 DOI: 10.1371/journal.pone.0010849] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
256 Cho JH, Kim EC, Son Y, Lee DW, Park YS, Choi JH, Cho KH, Kwon KS, Kim JR. CD9 induces cellular senescence and aggravates atherosclerotic plaque formation. Cell Death Differ 2020;27:2681-96. [PMID: 32346137 DOI: 10.1038/s41418-020-0537-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
257 Zhang J, Gao X, Schmit F, Adelmant G, Eck MJ, Marto JA, Zhao JJ, Roberts TM. CRKL Mediates p110β-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells. Cell Rep 2017;20:549-57. [PMID: 28723560 DOI: 10.1016/j.celrep.2017.06.054] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
258 Braccini L, Ciraolo E, Martini M, Pirali T, Germena G, Rolfo K, Hirsch E. PI3K keeps the balance between metabolism and cancer. Advances in Biological Regulation 2012;52:389-405. [DOI: 10.1016/j.jbior.2012.04.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
259 Majdalawieh AF, Massri M, Ro HS. AEBP1 is a Novel Oncogene: Mechanisms of Action and Signaling Pathways. J Oncol 2020;2020:8097872. [PMID: 32565808 DOI: 10.1155/2020/8097872] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
260 Qu J, Zheng B, Ohuchida K, Feng H, Chong SJF, Zhang X, Liang R, Liu Z, Shirahane K, Mizumoto K, Gong P, Nakamura M. PIK3CB is involved in metastasis through the regulation of cell adhesion to collagen I in pancreatic cancer. J Adv Res 2021;33:127-40. [PMID: 34603784 DOI: 10.1016/j.jare.2021.02.002] [Reference Citation Analysis]
261 Abdul SN, Ab Mutalib NS, Sean KS, Syafruddin SE, Ishak M, Sagap I, Mazlan L, Rose IM, Abu N, Mokhtar NM, Jamal R. Molecular Characterization of Somatic Alterations in Dukes' B and C Colorectal Cancers by Targeted Sequencing. Front Pharmacol 2017;8:465. [PMID: 28769798 DOI: 10.3389/fphar.2017.00465] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
262 Juvin V, Malek M, Anderson KE, Dion C, Chessa T, Lecureuil C, Ferguson GJ, Cosulich S, Hawkins PT, Stephens LR. Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines. PLoS One 2013;8:e75045. [PMID: 24124465 DOI: 10.1371/journal.pone.0075045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
263 Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS. Targeting EGFR resistance networks in head and neck cancer. Cell Signal. 2009;21:1255-1268. [PMID: 19258037 DOI: 10.1016/j.cellsig.2009.02.021] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
264 Psyrri A, Seiwert TY, Jimeno A. Molecular pathways in head and neck cancer: EGFR, PI3K, and more. Am Soc Clin Oncol Educ Book 2013;:246-55. [PMID: 23714515 DOI: 10.14694/EdBook_AM.2013.33.246] [Cited by in Crossref: 8] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
265 Zhang C, Xu B, Liu P. Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer. Tumour Biol 2016;37:14831-9. [PMID: 27639383 DOI: 10.1007/s13277-016-5381-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
266 Spangle JM, Roberts TM. Epigenetic regulation of RTK signaling. J Mol Med (Berl) 2017;95:791-8. [PMID: 28589435 DOI: 10.1007/s00109-017-1546-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
267 Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, Hsiao K, Yuan J, Green J, Ospina B, Yu Q, Ostrom L, Fordjour P, Anderson DL, Monahan JE, Kelleher JF, Peukert S, Pan S, Wu X, Maira SM, García-Echeverría C, Briggs KJ, Watkins DN, Yao YM, Lengauer C, Warmuth M, Sellers WR, Dorsch M. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010;2:51ra70. [PMID: 20881279 DOI: 10.1126/scitranslmed.3001599] [Cited by in Crossref: 317] [Cited by in F6Publishing: 318] [Article Influence: 28.8] [Reference Citation Analysis]
268 Zarif JC, Lamb LE, Schulz VV, Nollet EA, Miranti CK. Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase. Oncotarget 2015;6:6862-76. [PMID: 25730905 DOI: 10.18632/oncotarget.3119] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
269 Wang Y, Lee YM, Baitsch L, Huang A, Xiang Y, Tong H, Lako A, Von T, Choi C, Lim E, Min J, Li L, Stegmeier F, Schlegel R, Eck MJ, Gray NS, Mitchison TJ, Zhao JJ. MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. Elife 2014;3:e01763. [PMID: 24844244 DOI: 10.7554/eLife.01763] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 7.9] [Reference Citation Analysis]
270 Jenkins PM, Vasavda C, Hostettler J, Davis JQ, Abdi K, Bennett V. E-cadherin polarity is determined by a multifunction motif mediating lateral membrane retention through ankyrin-G and apical-lateral transcytosis through clathrin. J Biol Chem 2013;288:14018-31. [PMID: 23530049 DOI: 10.1074/jbc.M113.454439] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
271 Mourikis TP, Benedetti L, Foxall E, Temelkovski D, Nulsen J, Perner J, Cereda M, Lagergren J, Howell M, Yau C, Fitzgerald RC, Scaffidi P; Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium, Ciccarelli FD. Patient-specific cancer genes contribute to recurrently perturbed pathways and establish therapeutic vulnerabilities in esophageal adenocarcinoma. Nat Commun. 2019;10:3101. [PMID: 31308377 DOI: 10.1038/s41467-019-10898-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
272 Zecchin D, Moore C, Michailidis F, Horswell S, Rana S, Howell M, Downward J. Combined targeting of G protein-coupled receptor and EGF receptor signaling overcomes resistance to PI3K pathway inhibitors in PTEN-null triple negative breast cancer. EMBO Mol Med 2020;12:e11987. [PMID: 32672423 DOI: 10.15252/emmm.202011987] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
273 Kim J, Hong S, Hong S. Discovery of new aminopyrimidine-based phosphoinositide 3-kinase beta (PI3Kβ) inhibitors with selectivity over PI3Kα. Bioorganic & Medicinal Chemistry Letters 2011;21:6977-81. [DOI: 10.1016/j.bmcl.2011.09.118] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
274 Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M, Dancey JE, Piccart-Gebhart MJ. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev. 2013;39:935-946. [PMID: 23643661 DOI: 10.1016/j.ctrv.2013.03.009] [Cited by in Crossref: 216] [Cited by in F6Publishing: 207] [Article Influence: 24.0] [Reference Citation Analysis]
275 Zhang J, Roberts TM, Shivdasani RA. Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology. 2011;141:50-61. [PMID: 21723986 DOI: 10.1053/j.gastro.2011.05.010] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 6.5] [Reference Citation Analysis]
276 Leroy C, Ramos P, Cornille K, Bonenfant D, Fritsch C, Voshol H, Bentires-Alj M. Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition. Breast Cancer Res 2016;18:41. [PMID: 27048245 DOI: 10.1186/s13058-016-0697-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
277 Murphy CG, Dickler MN. Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies. Endocr Relat Cancer. 2016;23:R337-R352. [PMID: 27406875 DOI: 10.1530/erc-16-0121] [Cited by in Crossref: 60] [Cited by in F6Publishing: 38] [Article Influence: 10.0] [Reference Citation Analysis]
278 Zhang L, Liu X, Liu J, Ma X, Zhou Z, Song Y, Cao B. miR-26a promoted endometrial epithelium cells (EECs) proliferation and induced stromal cells (ESCs) apoptosis via the PTEN-PI3K/AKT pathway in dairy goats. J Cell Physiol 2018;233:4688-706. [PMID: 29115668 DOI: 10.1002/jcp.26252] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
279 Zhang Y, Park E, Kim CS, Paik JH. ZNF365 promotes stalled replication forks recovery to maintain genome stability. Cell Cycle 2013;12:2817-28. [PMID: 23966166 DOI: 10.4161/cc.25882] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
280 Rabinovsky R, Pochanard P, McNear C, Brachmann SM, Duke-Cohan JS, Garraway LA, Sellers WR. p85 Associates with unphosphorylated PTEN and the PTEN-associated complex. Mol Cell Biol 2009;29:5377-88. [PMID: 19635806 DOI: 10.1128/MCB.01649-08] [Cited by in Crossref: 70] [Cited by in F6Publishing: 49] [Article Influence: 5.4] [Reference Citation Analysis]
281 Klarenbeek S, van Miltenburg MH, Jonkers J. Genetically engineered mouse models of PI3K signaling in breast cancer. Mol Oncol 2013;7:146-64. [PMID: 23478237 DOI: 10.1016/j.molonc.2013.02.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
282 Mehra R, Serebriiskii IG, Dunbrack RL Jr, Robinson MK, Burtness B, Golemis EA. Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resist Updat 2011;14:260-79. [PMID: 21920801 DOI: 10.1016/j.drup.2011.08.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
283 Gyori D, Chessa T, Hawkins PT, Stephens LR. Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment. Cancers (Basel) 2017;9:E24. [PMID: 28273837 DOI: 10.3390/cancers9030024] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
284 Yuzugullu H, Baitsch L, Von T, Steiner A, Tong H, Ni J, Clayton LK, Bronson R, Roberts TM, Gritsman K, Zhao JJ. A PI3K p110β-Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis. Nat Commun 2015;6:8501. [PMID: 26442967 DOI: 10.1038/ncomms9501] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
285 Costa C, Hirsch E. More than just kinases: the scaffolding function of PI3K. Curr Top Microbiol Immunol 2010;346:171-81. [PMID: 20563705 DOI: 10.1007/82_2010_57] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
286 Reed DE, Shokat KM. INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC. Mol Cancer Res 2017;15:765-75. [PMID: 28196852 DOI: 10.1158/1541-7786.MCR-16-0183] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 3.8] [Reference Citation Analysis]
287 Tervonen TA, Partanen JI, Saarikoski ST, Myllynen M, Marques E, Paasonen K, Moilanen A, Wohlfahrt G, Kovanen PE, Klefstrom J. Faulty Epithelial Polarity Genes and Cancer. Elsevier; 2011. pp. 97-161. [DOI: 10.1016/b978-0-12-385524-4.00003-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
288 Cui B, Tao J, Yang Y. Studies on the expression patterns of class I PI3K catalytic subunits and its prognostic significance in colorectal cancer. Cell Biochem Biophys. 2012;62:47-54. [PMID: 21910030 DOI: 10.1007/s12013-011-9257-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
289 Mullane SA, Van Allen EM. Precision medicine for advanced prostate cancer. Curr Opin Urol 2016;26:231-9. [PMID: 26909474 DOI: 10.1097/MOU.0000000000000278] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
290 Bresnick AR, Backer JM. PI3Kβ-A Versatile Transducer for GPCR, RTK, and Small GTPase Signaling. Endocrinology 2019;160:536-55. [PMID: 30601996 DOI: 10.1210/en.2018-00843] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
291 Piddock RE, Bowles KM, Rushworth SA. The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma. Cancers (Basel) 2017;9:E29. [PMID: 28350342 DOI: 10.3390/cancers9040029] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
292 Wang Q, Weisberg E, Zhao JJ. The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome. Cell Cycle 2013;12:3589-93. [PMID: 24131925 DOI: 10.4161/cc.26812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
293 Kong DX, Yamori T. ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system. Acta Pharmacol Sin. 2010;31:1189-1197. [PMID: 20729870 DOI: 10.1038/aps.2010.150] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 4.0] [Reference Citation Analysis]
294 Yan Y, Huang H. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer. In: Dehm SM, Tindall DJ, editors. Prostate Cancer. Cham: Springer International Publishing; 2019. pp. 319-31. [DOI: 10.1007/978-3-030-32656-2_14] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
295 Ghigo A, Morello F, Perino A, Hirsch E. Phosphoinositide 3-kinases in health and disease. Subcell Biochem 2012;58:183-213. [PMID: 22403077 DOI: 10.1007/978-94-007-3012-0_6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
296 Giordanetto F, Wållberg A, Cassel J, Ghosal S, Kossenjans M, Yuan Z, Wang X, Liang L. Discovery of 4-morpholino-pyrimidin-6-one and 4-morpholino-pyrimidin-2-one-containing Phosphoinositide 3-kinase (PI3K) p110β isoform inhibitors through structure-based fragment optimisation. Bioorganic & Medicinal Chemistry Letters 2012;22:6665-70. [DOI: 10.1016/j.bmcl.2012.08.101] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
297 Wang Y, Li Y, Guo C, Lu Q, Wang W, Jia Z, Chen P, Ma K, Reinberg D, Zhou C. ISL1 and JMJD3 synergistically control cardiac differentiation of embryonic stem cells. Nucleic Acids Res 2016;44:6741-55. [PMID: 27105846 DOI: 10.1093/nar/gkw301] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
298 Zhao HF, Wang J, Shao W, Wu CP, Chen ZP, To ST, Li WP. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol Cancer 2017;16:100. [PMID: 28592260 DOI: 10.1186/s12943-017-0670-3] [Cited by in Crossref: 95] [Cited by in F6Publishing: 100] [Article Influence: 19.0] [Reference Citation Analysis]
299 Wang Y, Zhou D, Phung S, Masri S, Smith D, Chen S. SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells. Mol Endocrinol 2011;25:72-82. [PMID: 21084382 DOI: 10.1210/me.2010-0294] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
300 Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28:1075-1083. [PMID: 20085938 DOI: 10.1200/jco.2009.25.3641] [Cited by in Crossref: 857] [Cited by in F6Publishing: 458] [Article Influence: 71.4] [Reference Citation Analysis]
301 Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J, Moustafa Z, Thomas RK, Greulich H, Schinzel A, Zaghlul S, Batt D, Ettenberg S, Meyerson M, Schoeberl B, Kung AL, Hahn WC, Drapkin R, Livingston DM, Liu JF. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 2010;17:298-310. [PMID: 20227043 DOI: 10.1016/j.ccr.2009.12.047] [Cited by in Crossref: 165] [Cited by in F6Publishing: 146] [Article Influence: 13.8] [Reference Citation Analysis]
302 Vogt PK. PI3K p110β: more tightly controlled or constitutively active? Mol Cell 2011;41:499-501. [PMID: 21362546 DOI: 10.1016/j.molcel.2011.02.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
303 Pridham KJ, Le L, Guo S, Varghese RT, Algino S, Liang Y, Fajardin R, Rodgers CM, Simonds GR, Kelly DF, Sheng Z. PIK3CB/p110β is a selective survival factor for glioblastoma. Neuro Oncol 2018;20:494-505. [PMID: 29016844 DOI: 10.1093/neuonc/nox181] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
304 Mazloumi Gavgani F, Smith Arnesen V, Jacobsen RG, Krakstad C, Hoivik EA, Lewis AE. Class I Phosphoinositide 3-Kinase PIK3CA/p110α and PIK3CB/p110β Isoforms in Endometrial Cancer. Int J Mol Sci 2018;19:E3931. [PMID: 30544563 DOI: 10.3390/ijms19123931] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
305 Alfieri R, Giovannetti E, Bonelli M, Cavazzoni A. New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN/Focal Adhesion Kinase Pathway. Front Oncol 2017;7:170. [PMID: 28848709 DOI: 10.3389/fonc.2017.00170] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
306 Nadel G, Yao Z, Wainstein E, Cohen I, Ben-Ami I, Schajnovitz A, Maik-Rachline G, Naor Z, Horwitz BA, Seger R. GqPCR-stimulated dephosphorylation of AKT is induced by an IGBP1-mediated PP2A switch. Cell Commun Signal 2022;20:5. [PMID: 34998390 DOI: 10.1186/s12964-021-00805-z] [Reference Citation Analysis]
307 Zardavas D, Fumagalli D, Loi S. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers? Curr Opin Oncol 2012;24:623-34. [PMID: 22960556 DOI: 10.1097/CCO.0b013e328358a2b5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 4.1] [Reference Citation Analysis]
308 Marques RB, Aghai A, de Ridder CMA, Stuurman D, Hoeben S, Boer A, Ellston RP, Barry ST, Davies BR, Trapman J, van Weerden WM. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models. Eur Urol 2015;67:1177-85. [PMID: 25220373 DOI: 10.1016/j.eururo.2014.08.053] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 7.5] [Reference Citation Analysis]
309 Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550-562. [PMID: 19629070 DOI: 10.1038/nrc2664] [Cited by in Crossref: 1656] [Cited by in F6Publishing: 1569] [Article Influence: 127.4] [Reference Citation Analysis]
310 Workman P, Clarke PA, Raynaud FI, van Montfort RL. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res. 2010;70:2146-2157. [PMID: 20179189 DOI: 10.1158/0008-5472.CAN-09-4355] [Cited by in Crossref: 206] [Cited by in F6Publishing: 99] [Article Influence: 17.2] [Reference Citation Analysis]
311 Henry WS, Laszewski T, Tsang T, Beca F, Beck AH, McAllister SS, Toker A. Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling. Cancer Res. 2017;77:790-801. [PMID: 27940576 DOI: 10.1158/0008-5472.can-16-2400] [Cited by in Crossref: 51] [Cited by in F6Publishing: 37] [Article Influence: 8.5] [Reference Citation Analysis]
312 Saralamma VVG, Vetrivel P, Lee HJ, Kim SM, Ha SE, Murugesan R, Kim EH, Heo JD, Kim GS. Comparative proteomic analysis uncovers potential biomarkers involved in the anticancer effect of Scutellarein in human gastric cancer cells. Oncol Rep 2020;44:939-58. [PMID: 32705238 DOI: 10.3892/or.2020.7677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
313 Tan DS, Camilleri-Broët S, Tan EH, Alifano M, Lim WT, Bobbio A, Zhang S, Ng QS, Ang MK, Iyer NG, Takano A, Lim KH, Régnard JF, Tan P, Broët P. Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics. Int J Cancer 2014;135:1092-100. [PMID: 24482041 DOI: 10.1002/ijc.28750] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
314 Green AS, Maciel TT, Hospital MA, Yin C, Mazed F, Townsend EC, Pilorge S, Lambert M, Paubelle E, Jacquel A, Zylbersztejn F, Decroocq J, Poulain L, Sujobert P, Jacque N, Adam K, So JC, Kosmider O, Auberger P, Hermine O, Weinstock DM, Lacombe C, Mayeux P, Vanasse GJ, Leung AY, Moura IC, Bouscary D, Tamburini J. Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia. Sci Adv 2015;1:e1500221. [PMID: 26601252 DOI: 10.1126/sciadv.1500221] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
315 Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9:28-39. [PMID: 19104514 DOI: 10.1038/nrc2559] [Cited by in Crossref: 1756] [Cited by in F6Publishing: 1593] [Article Influence: 135.1] [Reference Citation Analysis]
316 Goulielmaki E, Bermudez-Brito M, Andreou M, Tzenaki N, Tzardi M, de Bree E, Tsentelierou E, Makrigiannakis A, Papakonstanti EA. Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages. Cell Death Dis 2018;9:678. [PMID: 29880805 DOI: 10.1038/s41419-018-0717-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
317 Sinha S, Renganathan A, Nagendra PB, Bhat V, Mathew BS, Rao MRS. AEBP1 down regulation induced cell death pathway depends on PTEN status of glioma cells. Sci Rep 2019;9:14577. [PMID: 31601918 DOI: 10.1038/s41598-019-51068-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
318 Shuttleworth S, Silva F, Tomassi C, Cecil A, Hill T, Rogers H, Townsend P. Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases. Prog Med Chem 2009;48:81-131. [PMID: 21544958 DOI: 10.1016/s0079-6468(09)04803-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
319 Wang G, Chen C, Yang R, Cao X, Lai S, Luo X, Feng Y, Xia X, Gong J, Hu J. p55PIK-PI3K stimulates angiogenesis in colorectal cancer cell by activating NF-κB pathway. Angiogenesis 2013;16:561-73. [PMID: 23354733 DOI: 10.1007/s10456-013-9336-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
320 Dreyling M, Amador V, Callanan M, Jerkeman M, Le Gouill S, Pott C, Rule S, Zaja F; European Mantle Cell Lymphoma Network. Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma 2015;56:866-76. [PMID: 25015778 DOI: 10.3109/10428194.2014.940584] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
321 Teplyakov E, Wu Q, Liu J, Pugacheva EM, Loukinov D, Boukaba A, Lobanenkov V, Strunnikov A. The downregulation of putative anticancer target BORIS/CTCFL in an addicted myeloid cancer cell line modulates the expression of multiple protein coding and ncRNA genes. Oncotarget 2017;8:73448-68. [PMID: 29088719 DOI: 10.18632/oncotarget.20627] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
322 Siroy AE, Davies MA, Lazar AJ. The PI3K-AKT Pathway in Melanoma. In: Torres-cabala CA, Curry JL, editors. Genetics of Melanoma. New York: Springer; 2016. pp. 165-80. [DOI: 10.1007/978-1-4939-3554-3_7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
323 Heavey S, O’byrne KJ, Gately K. Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. Cancer Treatment Reviews 2014;40:445-56. [DOI: 10.1016/j.ctrv.2013.08.006] [Cited by in Crossref: 80] [Cited by in F6Publishing: 85] [Article Influence: 10.0] [Reference Citation Analysis]
324 Jenkins PM, He M, Bennett V. Dynamic spectrin/ankyrin-G microdomains promote lateral membrane assembly by opposing endocytosis. Sci Adv 2015;1:e1500301. [PMID: 26523289 DOI: 10.1126/sciadv.1500301] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
325 Yang X, Yang JA, Liu BH, Liao JM, Yuan FE, Tan YQ, Chen QX. TGX-221 inhibits proliferation and induces apoptosis in human glioblastoma cells. Oncol Rep 2017;38:2836-42. [PMID: 29048665 DOI: 10.3892/or.2017.5991] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
326 Cheung LW, Mills GB. Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment. Pharmacogenomics 2016;17:297-307. [PMID: 26807692 DOI: 10.2217/pgs.15.174] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
327 Subramaniam PS, Whye DW, Efimenko E, Chen J, Tosello V, De Keersmaecker K, Kashishian A, Thompson MA, Castillo M, Cordon-Cardo C, Davé UP, Ferrando A, Lannutti BJ, Diacovo TG. Targeting nonclassical oncogenes for therapy in T-ALL. Cancer Cell 2012;21:459-72. [PMID: 22516257 DOI: 10.1016/j.ccr.2012.02.029] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 7.2] [Reference Citation Analysis]
328 Tian J, Zhu Y, Rao M, Cai Y, Lu Z, Zou D, Peng X, Ying P, Zhang M, Niu S, Li Y, Zhong R, Chang J, Miao X. N6-methyladenosine mRNA methylation of PIK3CB regulates AKT signalling to promote PTEN-deficient pancreatic cancer progression. Gut 2020;69:2180-92. [PMID: 32312789 DOI: 10.1136/gutjnl-2019-320179] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
329 Frank SB, Schulz VV, Miranti CK. A streamlined method for the design and cloning of shRNAs into an optimized Dox-inducible lentiviral vector. BMC Biotechnol 2017;17:24. [PMID: 28245848 DOI: 10.1186/s12896-017-0341-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
330 Rogers MA, Kalter V, Strowitzki M, Schneider M, Lichter P. IGF2 knockdown in two colorectal cancer cell lines decreases survival, adhesion and modulates survival-associated genes. Tumour Biol 2016;37:12485-95. [PMID: 27337954 DOI: 10.1007/s13277-016-5115-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
331 Wymann M. PI3Ks—Drug Targets in Inflammation and Cancer. In: Balla T, Wymann M, York JD, editors. Phosphoinositides I: Enzymes of Synthesis and Degradation. Dordrecht: Springer Netherlands; 2012. pp. 111-81. [DOI: 10.1007/978-94-007-3012-0_5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
332 Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, Perez-Garcia J, Galvan P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty S, Scaltriti M, Baselga J. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med 2015;7:283ra51. [PMID: 25877889 DOI: 10.1126/scitranslmed.aaa4442] [Cited by in Crossref: 185] [Cited by in F6Publishing: 161] [Article Influence: 30.8] [Reference Citation Analysis]
333 Cumberbatch M, Tang X, Beran G, Eckersley S, Wang X, Ellston RP, Dearden S, Cosulich S, Smith PD, Behrens C, Kim ES, Su X, Fan S, Gray N, Blowers DP, Wistuba II, Womack C. Identification of a subset of human non-small cell lung cancer patients with high PI3Kβ and low PTEN expression, more prevalent in squamous cell carcinoma. Clin Cancer Res 2014;20:595-603. [PMID: 24284056 DOI: 10.1158/1078-0432.CCR-13-1638] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
334 Phillips LS, Thompson CL, Merkulova A, Plummer SJ, Tucker TC, Casey G, Li L. No association between phosphatase and tensin homolog genetic polymorphisms and colon cancer. World J Gastroenterol 2009; 15(30): 3771-3775 [PMID: 19673018 DOI: 10.3748/wjg.15.3771] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
335 Cretella D, Digiacomo G, Giovannetti E, Cavazzoni A. PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition. Cancers (Basel) 2019;11:E1318. [PMID: 31500143 DOI: 10.3390/cancers11091318] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
336 Bucheit AD, Davies MA. Emerging insights into resistance to BRAF inhibitors in melanoma. Biochem Pharmacol 2014;87:381-9. [PMID: 24291778 DOI: 10.1016/j.bcp.2013.11.013] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 6.1] [Reference Citation Analysis]
337 Foukas LC, Berenjeno IM, Gray A, Khwaja A, Vanhaesebroeck B. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci U S A 2010;107:11381-6. [PMID: 20534549 DOI: 10.1073/pnas.0906461107] [Cited by in Crossref: 113] [Cited by in F6Publishing: 103] [Article Influence: 9.4] [Reference Citation Analysis]
338 Brooks K, Ranall M, Spoerri L, Stevenson A, Gunasingh G, Pavey S, Meunier F, Gonda TJ, Gabrielli B. Decatenation checkpoint-defective melanomas are dependent on PI3K for survival. Pigment Cell Melanoma Res 2014;27:813-21. [DOI: 10.1111/pcmr.12268] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
339 Yu M, Grady WM. Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer. Therap Adv Gastroenterol 2012;5:319-37. [PMID: 22973417 DOI: 10.1177/1756283X12448456] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
340 Cen B, Wei Y, Huang W, Teng M, He S, Li J, Wang W, He G, Bai X, Liu X, Yuan Y, Pan X, Ji A. An Efficient Bivalent Cyclic RGD-PIK3CB siRNA Conjugate for Specific Targeted Therapy against Glioblastoma In Vitro and In Vivo. Mol Ther Nucleic Acids 2018;13:220-32. [PMID: 30312846 DOI: 10.1016/j.omtn.2018.09.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
341 Obasi TC, Braicu C, Iacob BC, Bodoki E, Jurj A, Raduly L, Oniga I, Berindan-Neagoe I, Oprean R. Securidaca-saponins are natural inhibitors of AKT, MCL-1, and BCL2L1 in cervical cancer cells. Cancer Manag Res 2018;10:5709-24. [PMID: 30532593 DOI: 10.2147/CMAR.S163328] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
342 Ranzani M, Annunziato S, Calabria A, Brasca S, Benedicenti F, Gallina P, Naldini L, Montini E. Lentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies. Mol Ther 2014;22:2056-68. [PMID: 25195596 DOI: 10.1038/mt.2014.174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
343 Heffron TP, Heald RA, Ndubaku C, Wei B, Augistin M, Do S, Edgar K, Eigenbrot C, Friedman L, Gancia E, Jackson PS, Jones G, Kolesnikov A, Lee LB, Lesnick JD, Lewis C, McLean N, Mörtl M, Nonomiya J, Pang J, Price S, Prior WW, Salphati L, Sideris S, Staben ST, Steinbacher S, Tsui V, Wallin J, Sampath D, Olivero AG. The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326). J Med Chem 2016;59:985-1002. [PMID: 26741947 DOI: 10.1021/acs.jmedchem.5b01483] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 9.3] [Reference Citation Analysis]
344 Atreya CE, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, Stone S, Shokat KM, Warren RS. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer Med. 2013;2:496-506. [PMID: 24156022 DOI: 10.1002/cam4.97] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
345 Pridham KJ, Varghese RT, Sheng Z. The Role of Class IA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunits in Glioblastoma. Front Oncol 2017;7:312. [PMID: 29326882 DOI: 10.3389/fonc.2017.00312] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
346 Workman P, Clarke P. PI3 Kinase in Cancer: From Biology to Clinic. American Society of Clinical Oncology Educational Book 2012. [DOI: 10.14694/edbook_am.2012.32.89] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
347 Xiao XH, Lv LC, Duan J, Wu YM, He SJ, Hu ZZ, Xiong LX. Regulating Cdc42 and Its Signaling Pathways in Cancer: Small Molecules and MicroRNA as New Treatment Candidates. Molecules 2018;23:E787. [PMID: 29596304 DOI: 10.3390/molecules23040787] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
348 Will M, Qin AC, Toy W, Yao Z, Rodrik-Outmezguine V, Schneider C, Huang X, Monian P, Jiang X, de Stanchina E, Baselga J, Liu N, Chandarlapaty S, Rosen N. Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov 2014;4:334-47. [PMID: 24436048 DOI: 10.1158/2159-8290.CD-13-0611] [Cited by in Crossref: 123] [Cited by in F6Publishing: 78] [Article Influence: 15.4] [Reference Citation Analysis]
349 Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15:7-24. [PMID: 25533673 DOI: 10.1038/nrc3860] [Cited by in Crossref: 709] [Cited by in F6Publishing: 657] [Article Influence: 101.3] [Reference Citation Analysis]